University of South Carolina

Scholar Commons
Theses and Dissertations
2016

Differences In Resting-State Functional Connectivity Of Chronic
Migraine, With And Without Medication Overuse Headache, And
The Effectiveness Of Sphenopalatine Ganglion Block As A
Treatment For Repairing Dysfunctional Connectivity.
Kaitlin Krebs
University of South Carolina

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Biomedical and Dental Materials Commons, and the Other Medical Sciences Commons

Recommended Citation
Krebs, K.(2016). Differences In Resting-State Functional Connectivity Of Chronic Migraine, With And
Without Medication Overuse Headache, And The Effectiveness Of Sphenopalatine Ganglion Block As A
Treatment For Repairing Dysfunctional Connectivity.. (Master's thesis). Retrieved from
https://scholarcommons.sc.edu/etd/3997

This Open Access Thesis is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and
Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
digres@mailbox.sc.edu.

DIFFERENCES IN RESTING-STATE FUNCTIONAL CONNECTIVITY OF CHRONIC
MIGRAINE, WITH AND WITHOUT MEDICATION OVERUSE HEADACHE, AND THE
EFFECTIVENESS OF SPHENOPALATINE GANGLION BLOCK AS A TREATMENT
FOR REPAIRING DYSFUNCTIONAL CONNECTIVITY.
by
Kaitlin Krebs
Bachelor of Arts
University of South Carolina, 2013

Submitted in Partial Fulfillment of the Requirements
For the Degree of Master of Science in
Biomedical Science
School of Medicine
University of South Carolina
2016
Accepted by:
Michelle Androulakis, Director of Thesis
David Mott, Reader
Roger Newman-Norlund, Reader
Cheryl L. Addy, Vice Provost and Dean of the Graduate School

© Copyright by Kaitlin Krebs, 2016
All Rights Reserved.

ii

DEDICATION
I dedicate this thesis to my amazing partner in crime, Taylor Hanayik, and to the
rest of my wonderfully crazy family. I would not have made it to this point without the
continuous support from all of you! To my mother, Beth Krebs, for your teaching me to
be kind and compassionate. To my father, Fred Krebs, for teaching me that there is
nothing in this world that you can’t figure out if you just google it enough. To my sisters,
Jennica and Courtney, thank you for being born before me (because we all know the
youngest is always the smartest), but also for providing me with great role models to look
up to. To both my bother-in-laws, Michael and Joel, thank you for making family
gatherings so much fun and for playing peace keepers between my sisters and I after a
heated game of scrabble. To my nephew, Kellen, I know you are only 9 months old right
now and can’t read this, but if you ever pick this up when visiting your crazy aunt, know
that you are loved so much by all of us, and always cherish your family because you have
an excellent one.
And finally, to Taylor, you are the most incredible person I have ever met. I
appreciate everything you do for me; for making me laugh when I get mad, for telling me
“you’re not dying” when I am being dramatic, for letting me have the last bit of cake, and
for putting up with my crazy Krebs nature. Without you, I wouldn’t be who I am, and I
am so lucky to journey through life with you.

iii

ACKNOWLEDGEMENTS
I would like to thank my mentor, Michelle Androulakis, for the continuous
support in helping me achieve this degree and for being an amazing role model, teacher,
and friend. You are truly a genuine doctor and teacher that I was very fortunate to have
you as a mentor. Additional thanks to the other members of my committee, Dr. David
Mott and Dr. Roger Newman-Norlund, for taking the time to help with this thesis.
Many thanks to Chris Rorden, for introducing me to the world of science, for
creating tools for the technological impaired (which were gratefully used in this thesis),
and for having some of the best stories. To Tianming Zhang, for helping with the
statistics used in this thesis.
I lastly want to thank Dr. Souvik Sen, Dr. Priyantha Herath, Amy Seidel, and the
rest of the Neurology Department, for their guidance and support in helping me earn this
degree.

iv

ABSTRACT
Chronic Migraine (CM) is a debilitating neurological condition that occurs when
the migraine frequency progresses to a chronic state of more than 15 headache days per
month. The overuse of analgesic medication (MOH) is one of the most prominent risk
factor of this chronification and little is known about why it is a cause. The repetitive
inhibition of the Sphenopalatine Ganglion is one promising treatment that is used to treat
chronic migraine. The purpose of this study is to determine if a specific pattern of
disruption is present for chronic migraine, both with and without medication overuse
headache, and if that disruption can be normalized after a series of Sphenopalatine
Ganglion blocks. Resting state functional magnetic resonance imaging was used to
analyze differences in intrinsic functional networks between CM patients with and
without MOH, between each CM subgroup and age matched controls, and between a
subset of CM patients before and after they received a series of SPG treatment. Three
major intrinsic brain networks, including the Default Mode Network (DMN), Silence
Network (SN) and Executive Control Network (ECN), were statistically less coherent
with CM (both with MOH and without MOH) as compared to controls. There were also
specific patterns of disruption to the intranetwork connectivity in each CM subgroup as
compared to controls. After 6 weeks of treatment, overall improvements were seen in
both the DMN and ECN. Our results suggest that there are underlying differences
between CM with MOH and CM without MOH that may be caused by disruptions to
smaller systems that exist within the SN and ECN. Additionally, in CM without MOH, a
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disruption to the subcallosal area within the SN may be associated with the inability to
inhibit the thalamus from sending pain signals to pain processing areas, causing chronic
pain. This disruption was not seen in CM with MOH patients, suggesting that there is a
different disruption present which accelerates the chronification process. After six weeks
of SPG block treatment, overall improvements were seen in both the DMN and ECN,
suggesting this treatment can help the normalization of these networks.
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CHAPTER 1: INTRODUCTION
INTRODUCTION
Chronic migraine (CM) is a debilitating neurological condition that affects
approximately 140 million individuals in the global population and 8% of patients
with migraine (Buse et al., 2012; May & Schulte, 2016). It is characterized by pain
that is moderate to severe, pulsating/throbbing, and associated symptoms such as
increased sensitivity to sensory stimuli and nausea/vomiting (“Headache
Classification,” 2013). Migraine can be classified as either episodic, with 0 to 14
headache days per month, or chronic, with ≥ 15 headache days and 8 migraine days
per month (“Headache Classification,” 2013). While the majority of the migraine
population will stay in the classification of episodic migraines, approximately 2% to
3% of the patients will have their diagnosis transformed from episodic migraine to
chronic migraine (May & Schulte, 2016; Manack, Buse, & Lipton, 2011). This
transformation occurs when a patient’s headache frequency increases to more than 15
days per month, and migraine frequency more than 8 days per month (“Headache
Classification,” 2013).
The mechanisms of migraine chronification are not completely understood, but
several risk factors, such as heritability, genetics, stress, comorbid conditions, and
environmental exposures, have been found (Bigal & Lipton, 2006; Lipton & Bigal,
2005).
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One of the most prominent risk factors for migraine chronification is the overuse of
medications such as triptans, opioids, and other over the counter (OTC) analgesics
used for treating acute migraine attacks (May & Schulte, 2016; Katsarava et al., 2004;
Paemeleire et al., 2008). This secondary chronic headache disorder, known as
medication overuse headache (MOH), occurs when a patient, for more than 3 months,
takes triptans, opioids, or a combination of medication for more than 10 days/month or
simple analgesics for more than 15 days/month (Bigal & Lipton, 2006; Lipton &
Bigal, 2005). However, it is important to note that the chronification of migraine can
occur without any influence from medication overuse. Given that these different risk
factors both lead to chronic migraine, it is not clear if there is a similarity in the neural
mechanisms of these two disorders, however, with utilization of functional magnetic
resonance imaging (fMRI), possible differences in functional connectivity of brain
regions between the two groups can be investigated.
1.1 CHRONIC MIGRAINE AND RESTING STATE CONNECTIVITY:
Previous fMRI studies measuring blood oxygen level dependent (BOLD) signals
have identified several task-independent networks of brain areas that are functionally
linked during “intrinsic” brain activity (Fair et al., 2009). These networks are constructed
by determining the functional correlations among different brain regions, either at rest or
when evoked by a task (Fair et al., 2009). With the use of fMRI, certain clinical
conditions are often being researched to determine if there are associated disruptions to
these functional brain networks. The impact of migraine on functional brain connectivity
is one such clinical condition now gaining popularity, as multiple studies have shown
disrupted functional connectivity in individuals with migraines (Mathur et al., 2015;
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Russo et al., 2012; Tessitore et al., 2013; Xue et al., 2012; Schwedt et al., 2013).
Similarly, disrupted resting state connectivity has been reported in several different
chronic pain conditions, including chronic back pain, neuropathic pain, and fibromyalgia
(Baliki, Baria, & Apkarian, 2011; Baliki et al., 2012; Loggia et al., 2013; Tagliazucchi et
al., 2010; Cauda et al., 2009; Cifre et al., 2012; Napadow et al., 2010). As migraine is
largely accompanied by pain, variations in functional brain connectivity are thought to
occur from the overwhelming need for the perception of pain (Xue et al., 2012). The
perception of pain is a complex process that involves several brain regions, each
individually contributing to a part of this perceptual process (Peyron, Laurent, & GarciaLarrea, 2000).
Cognitive control is an important aspect of the perception of pain and has been the
focus of many migraine research studies (Schwedt et al., 2013). Evidence suggest that
persistent pain causes a reorganization of intrinsic brain networks, thus altering cognitive
processing (Schwedt et al., 2013). One study showed that migraineurs had greater evoked
pain related activity, compared to controls, in areas responsible with cognitive control
over pain processing, such as the right dorsolateral prefrontal cortex, premotor cortex,
and hippocampus (Schwedt et al., 2014a). Another study showed that when a painful
stimuli is administered during a difficult task, chronic migraine patients, as compared to
controls, had a widespread decrease in activation of task related brain areas that shared
pain processing. This suggests that cognitive resources in migraineurs were diverted to
“pain-reduction-related processes” (Mathur et al., 2015). Taken together, these findings
imply that changes in functional cognitive brain activity is due to the interaction between
overlapping pain networks and cognitive networks (Mathur et al., 2015).
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For the purposes of this study, the default mode, task positive, salience, and
executive control networks were chosen due to their implications of dysregulation in
migraineurs (Russo et al., 2012; Tessitore et al., 2013; Xue et al., 2012; Schwedt et al.,
2013).
1.2 DEFAULT MODE AND TASK POSITIVE NETWORK:
The default mode network (DMN), also referred to as the task-negative network,
has been implicated in self-related cognition, with associated roles including
autobiographical, self-monitoring, and social functions (Li, Mai, & Liu, 2014; Raichle et
al., 2001). The DMN (Figure 1.1) includes the bilateral lateral parietal (LP), medial
prefrontal cortex (mPFC), and posterior cingulate cortex (PCC)/Precuneus regions (Fox
et al., 2005). The default mode network (DMN) is most notably associated with the task
positive network (TPN) due to its strong anti-correlation relationship of spontaneous
fluctuation in resting state signals over time (Fox et al., 2005; Biswal et al., 1995; Biswal
et al., 2010; Greicius et al., 2003). This relationship is illustrated best during attention
demanding cognitive tasks, which shows when the TPN is activated, the DMN will be
deactivated. The TPN functions as a complement to active cognitive processes such as
working memory, attention, and executive control (Hamilton et al., 2011). The TPN
(Figure 1.2) includes bilateral precentral sulcus/frontal eye fields (FEF), bilateral
intraparietal sulcus (IPS), and bilateral medial temporal (MT). Increased brain activity is
typically observed within this network in response to focused attention and goal-oriented
behavior (Fox et al., 2005). Both networks are reproducible within subjects and across
subjects using resting state fMRI (Biswal et al., 1995; Biswal et al., 2010; Shehzad et al.,
2009; Van Dijk & Alexander, 2014).
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FIGURE 1.1: Axial and Sagittal view of the DMN. (1) Medial Prefrontal, (2) Precuneus/PCC, (3) Left Lateral Parietal, (4) Right
Lateral Parietal. Images were made with “Surf Ice” (https://www.nitrc.org/projects/surfice/) using the exact MNI coordinate locations
and sphere sizes (15mm).
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FIGURE 1.2: Axial and Sagittal view of the TPN. (1) Left Precentral Sulcus/FEF, (2) Right Precentral Sulcus/FEF, (3) Left
Intraparietal Sulcus, (4) Right Intraparietal Sulcus, (5) Left Medial Temporal, (6) Right Medial Temporal. Images were made with
“Surf Ice” (https://www.nitrc.org/projects/surfice/) using the exact MNI coordinate locations and sphere sizes (15mm).

It is suggested that this dichotomous relationship is reflective of competition between the
processing of external and internal input, and proper communication between these two
networks is postulated to be crucial for proper cognitive function (Fox et al., 2005;
Wotruba et al., 2013). In the presence of pain, however, these two networks have shown
to be affected. Specifically, with the presence of simultaneously experienced pain, the
TPN is further enhanced, suggesting that pain acts as an additional cognitive load
(Seminowicz & Davis, 2007; Mantini et al., 2009; Weissman-Fogel et al., 2011). The
DMN, however, is deactivated when attending to painful stimuli (Mantini et al., 2009;
Weissman-Fogel et al., 2011; Kong et al., 2010; Loggia et al., 2012).
One issue with the TPN is this network is very dependent on what task is being
used, and can sometimes be co-activated with the DMN during autobiographical planning
tasks (Spreng & Grandy, 2010). Additionally, the TPN has faced a lot of criticism, due to
composition of two functionally and anatomically distinct networks that play different
roles in cognition (Spreng, 2012). The frontoparietal control network is more recently
being functionally coupled with the DMN due to its interactivity during internally
directed cognition (Gao & Lin, 2012; Deshpande, Santhanam, & Hu, 2011; Seeley et al.,
2007). There has been further dissociation of the frontoparietal network into two distinct
“Salience” and “Executive Control” networks, which roles broadly are to identify salient
information and how to act on that salient information (Seeley et al., 2007). For this
reason, the addition of these established networks, such as the salience and executive
control network, could provide a better understanding of this pain-cognition interaction.
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1.3 SALIENCE NETWORK:
The salience network (SN) is an important network for preparing a person for
action on objects or events that are significant at any given moment in time and plays a
critical function in cognitive control due to its role as a mediator between internal and
external action (Seeley et al., 2007). As such, abnormalities in this network could affect
or disrupt other networks, such as the DMN, due to its involvement in cognitive control
(Bonnelle et al., 2012). This network would most likely be active when a salient internal
or external stimulus requires action, such as being aware of pain or focusing on what
piece to move when playing chess (Seeley et al., 2007). The SN (Figure 1.3) includes the
bilateral dorsal anterior cingulate cortex (dACC), bilateral dorsolateral prefrontal cortex
(DLPFC), left frontal pole, bilateral hypothalamus, bilateral orbital frontal insula (Orb.
FI), paracingulate cortex, bilateral subcallosal area, bilateral supramarginal gyrus (SMG),
left periaqueductal gray (PAG), bilateral supplementary motor area (SMA)/pre SMA,
bilateral substantia nigra/ventral tegmental area (SN/VTA), bilateral superior temporal,
bilateral temporal pole, bilateral ventral striatum/pallidum (vSP), and right ventrolateral
PFC (VLPFC). Network associated paralimbic structures, such as dACC and orbital
frontal insula, have been found to be coactive in response to the emotion aspect of pain
(Seeley et al., 2007). Interestingly, the insula and DLPFC (two regions found in the SN)
have been postulated as “hubs” for dysregulation of intrinsic functional connectivity in
chronic pain related disorders (Cifre et al., 2012; Čeko et al., 2015). It has been shown
that reduced functional connectivity between SN and visual networks has been reported
(interictally) in migraine with aura patients (Niddam et al., 2015). Unfortunately, the SN
has not been adequately researched in the CM population (Schwedt et al., 2013)
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FIGURE 1.3: Axial and Sagittal view of the SN. (1) Left DLPFC, (2) Right DLPFC, (3) Right VLPFC, (4) Left frontal pole, (5) Left orbital frontal
insula, (6) Right orbital frontal insula, (7) Left temporal pole, (8) Right temporal pole, (9) Left SMA/pre SMA, (10) Right SMA/pre SMA, (11)
Paracingulate cortex,(12) Left dACC, (13) Right dACC, (14) Left subcallosal area,(15) Right subcallosal area, (16) Left periaqueductal gray (PAG), (17)
Left hypothalamus, (18) Right hypothalamus, (19) Right dorsomedial thalamus, (20) Left SN/VTA, (21) Right SN/VTA, (22) Left ventral
striatum/pallidum, (23) Right ventral striatum/ pallidum, (24) Left superior temporal, (25) Right superior temporal, (26) Left Supramarginal gyrus, (27)
Right Supramarginal gyrus. Images were made with “Surf Ice” (https://www.nitrc.org/projects/surfice/) using the exact MNI coordinate locations and
sphere sizes (15mm).

1.4 EXECUTIVE CONTROL NETWORK:
The executive control network (ECN) is associated with higher-order cognitive
processes such as attention and working memory. Its primary function is to direct
attention to salient input, maintaining relevant data in mind in order to select an action in
response to fluctuating environmental self-regulating conditions. This network (Figure
1.4) consists of the bilateral anterior thalamus, bilateral dorsolateral PFC (DLPFC),
bilateral dorsolateral PFC region of frontal eye fields (DLPFC/FEF), dorsal medial PFC
(dmPFC), right inferior frontal gyrus (IFG)/frontal operculum, right inferior temporal,
bilateral lateral parietal, left orbital frontal insula (OFI), bilateral ventrolateral PFC
(VLPFC), bilateral dorsal caudate, and right ventromedial caudate (Seeley et al., 2007). A
handful of studies have found that migraine with and without aura have reduced/disrupted
ECN, however, virtually no studies have looked at the ECN in chronic migraine patients
(Russo et al., 2012; Tessitore et al., 2013; Xue et al., 2012; Yu et al., 2012; Tessitore et
al., 2015).
1.5 NEUROIMAGING STUDIES OF MOH:
Very few neuroimaging studies exist which evaluate MOH, with even fewer that
compare CM w/ MOH to CM w/o MOH (Ferrero et al., 2012b, Zappaterra et al., 2011,
Lai et al., 2016; Chen et al., 2016). Most studies that do exist merely examine pain
perception in MOH patients, with most concluding that MOH patients exhibit a lower
pain threshold, even more so than chronic migraineurs, due to central sensitization
(Zappaterra et al., 2011; Munksgaard, Bendtsen, & Jensen, 2013; Perrotta et al., 2009;
Perrotta et al., 2012; Zappaterra et al., 2011). This lower threshold in MOH patients is
however reversible after detoxification (Munksgaard, Bendtsen, & Jensen, 2013).
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FIGURE 1.4: Axial and Sagittal view of the ECN. (1) Left DLPFC, (2) Right DLPFC, (3) Left DLPFC/FEF, (4) Right DLPFC/FEF,
(5) DMPFC, (6) Left VLPFC, (7) Right VLPFC, (8) Left Orbital Frontal Insula, (9) Right Inferior Frontal Gyrus, (10) Right Inferior
Temporal, (11) Left Lateral Parietal, (12) Right Lateral Parietal, (13) Left Dorsal Caudate, (14) Right Dorsal Caudate, (15) Right
Ventromedial Caudate, (16) Left Anterior Thalamus, (17) Right Anterior Thalamus. Images were made with “Surf Ice”
(https://www.nitrc.org/projects/surfice/) using the exact MNI coordinate locations and sphere sizes (15mm).

A similar reversible effect after detoxification is seen in a few functional
fMRI/PET studies (Ferrero et al., 2012a; Ferrero et al., 2012b; Grazzi et al., 2010; Fumal
et al., 2006). Areas of bilateral somatosensory cortex, bilateral inferior and superior
parietal lobe, and right supramarginal gyrus were hypoactive during pain related activity,
but was seen to reverse 6 months after detoxification (Ferrero et al., 2012a; Grazzi et al.,
2010; Chiapparini et al., 2009). A similar PET study comparing MOH/detoxified MOH
patients to healthy controls, revealed similar hypometabolic pain processing regions, such
as bilateral thalamus, OFC, ACC, insula, ventral striatum, and right inferior parietal lobe,
with all areas, except the OFC, recovering after detoxification (Fumal et al., 2006).
In a study which compared the task related activity of CM w/MOH and w/o MOH
to healthy controls, hyperactivity is present for both patient groups in the bilateral
VMPFC and PCC/Precuneus, however, hypoactivity in the SN/VTA was only seen in the
MOH patients. This same study also compared detoxified MOH patients to controls,
which revealed that the VMPFC and PCC/Precuneus hyperactivity had normalized, but
the hypoactivity in the SN/VTA was still persistent (Ferrero et al., 2012b).
It is important to note evidence, using voxel-based morphometry (VBM), that
MOH has a significant effect on gray matter volume (GMV) for the brain structures
involved in the DMN, SN, and ECN. (Chanraud et al., 2014; Riederer et al., 2012; Lai et
al., 2016). VBM studies report that MOH patients had a significant increase of GMV in
thalamus and ventral striatum; and a significant decrease of GMV in bilateral ACC, OFC,
insula, nucleus accumbens/rectal gyrus, inferior frontal gyrus, right DLPFC, left frontal
pole, and precuneus (Riederer et al., 2012; Lai et al., 2016). Additionally, GMV has been
negatively correlated with years with migraine in bilateral orbito-frontal, left superior
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frontal gyrus (frontal pole), left precuneus, right caudate, and right hippocampus
(Chanraud et al., 2014).
To our knowledge, there has only been one resting state functional connectivity
study, in which MOH was compared to controls and episodic migraineurs (Chanraud et
al., 2014). In this study, the precuneus was used as a seed region, therefore their results
are only comparable within the DMN. Lower functional connectivity was seen in
precuneus to right lateral parietal and right mPFC in the DMN (Chanraud et al., 2014).
1.6 TREATMENT OF CHRONIC MIGRAINE:
Currently, there are several different acute and preventative treatments available
for chronic migraine patients. However, these treatments are generally regarded as being
suboptimally effective, expensive, and likely to lead to multiple side effects (Magis,
Jensen, & Schoenen, 2012). The Sphenopalatine ganglion (SPG) has been a popular
clinical target for the treatment of headaches for nearly 100 years (Slunder, 1909).
The SPG is the largest extracranial, parasympathetic ganglion in the head, located
on each side of the pterygopalatine fossa (Lang, 1995). Within the SPG, there are both
parasympathetic and sympathetic fibers present, however, only the parasympathetic
fibers synapse within the SPG. Additionally, the SPG has a sensory component due to the
neural projections from the trigeminal nerve, which also passes through the SPG via the
maxillary division. The parasympathetic fibers that project from the SPG are distributed
to several glands, including the lacrimal, nasal, palatine, and pharyngeal gland, via the
ophthalmic and maxillary divisions of the trigeminal nerve. There are several branches
that project from the SPG towards the orbital cavity, which innervates the meningeal and
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cerebral blood vessels (Larsson et al., 1976; Nozaki et al., 1993; Ruskell, 2004; Suzuki &
Hardebo, 1992).
The SPG has often been thought to play a role in migraine pathogenesis through
activation of the trigemino-autonomic reflex (Khan, Schoene, & Ashina, 2014; Robbins
et al., 2015). A hypothesis called the “Unitary Hypothesis”, proposed by Burstein and
Jakubowski, suggests that the superior salivatory nucleus is the primary reactant for
multiple migraine triggers. The superior salivatory nucleus is a preganglionic
parasympathetic nucleus that receives inputs from multiple areas, such as hypothalamus,
limbic and cortical systems. These cortical and limbic centers, when triggered by
variations of stimuli (“migraine triggers”), would activate the superior salivatory nucleus,
and in turn, activate the SPG (Burstein & Jakubowski, 2005). The SPG then triggers a
vasodilation of the meningeal vessels, resulting in a release of inflammatory chemicals
that initiate migraine pain (Moskowitz, 1990; Goadsby, Lipton, & Ferrari, 2002).
This hypothesis implies that the SPG plays a key role in the activation of
migraine pain, thus creating a logical therapeutic target. The idea behind developing
therapeutic approaches to “block” the sphenopalatine ganglion lends itself to the unitary
hypothesis, in that inhibiting the parasympathetic outflow of the SPG will ultimately
inhibit pain and the autonomic symptoms that accompany migraine attacks (Robbins et
al., 2015). Another interesting theory behind SPG target therapy, is that by modulating
the autonomic nerve, there is a “neurophysiological reboot” that occurs in the
dysregulated central or trigeminal autonomic systems (Candido et al., 2013).
Since the discovery of the SPG, neuromodulation methods have included surgery,
electrical stimulation, microvascular decompression, and radiofrequency ablation; all of
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which are performed in a surgical setting. Unfortunately, these invasive methods were
often accompanied by extensive adverse events (Windsor & Jahnke, 2004; Candido et al.,
2013). With the increased interest in the SPG as a target for treatment, several new
medical devices have become available (Robbins et al., 2015). One of these devices, the
Tx360, was developed as a minimally invasive SPG modulation (Candido et al., 2013).
The Tx360 device has a soft, flexible applicator that is designed to curve around the
inferior turbinate in order to administer an anesthetic spray to the anterior, lateral, and
superior area of the mucosa that covers the SPG (Candido et al., 2013). This device
allows a more successful (and accurate) delivery of the sphenopalatine ganglion blocking
agent in a noninvasive manner (Candido et al., 2013). In the clinical setting, the SPG
blockade is used on chronic migraine patients, both with and without medication overuse
headache, in a series of twelve treatments that are administered over a 6-week period.
Though most of this treatment has been used in the refractory cluster headache
population, more clinical indications, such as chronic migraine, are being researched
(Cady et al., 2015a; Cady et al., 2015b). Recently, a double blinded, placebo controlled,
randomized clinical trial demonstrated the effectiveness of the FDA approved Tx360 on
chronic migraine (Cady et al., 2015a; Cady et al., 2015b). In this study, and an additional
follow up study by the same group, the Tx360 was shown to be a relatively inexpensive,
minimally invasive, and well tolerated treatment for Chronic Migraine (Cady et al.,
2015a; Cady et al., 2015b). This was seen by the significant improvement of migraine
disability and clinical outcomes, such as Headache Impact Scale (HIT-6), sleep
disturbance, and function at work, after 6 weeks of treatment.
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For a portion of the current study, we will examine the four intrinsic brain
networks listed earlier, both before and after a series of SPG blocks, to determine if there
is any change in patterns of functional connectivity.
1.7 SIGNIFICANCE:
Though there is a plethora of research on the pathophysiology and treatment of
migraine, little is known of the long term, lasting effects migraine has on brain structure
and function. Measuring the perception of pain can be difficult as individuals may
experience pain differently, therefore it is vital to determine another means of measuring
the long term effects of migraine. Chronic pain, as opposed to acute pain, has been linked
to impairments of interoceptive and cognitive control function due to the constant
demand of cognitive resources (Apkarian et al., 2004; McCracken & Iverson, 2001;
Eccleston & Crombez, 1999; Nes, Roach, & Segerstrom, 2009). As the DMN, SN, and
ECN have previously been used to test these interoceptive and cognitive control
functions, investigation into the specific effects that chronic migraine has on these
networks may prove to be a useful tool in understanding the complexities of this disorder,
and why the overuse of medication additionally contributes to chronification.
Using these same networks, additional information can be obtained by
investigating how treatments, such as the SPG block, alleviate some of the clinical
symptoms of chronic migraine. Furthermore, the conceptualization of using intrinsic
brain networks to quantify restoration of functional connectivity to a normalized state
could ultimately prove to be a useful tool for the testing and development of therapeutic
treatments (Maleki & Gollub, 2016).
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1.8 SPECIFIC AIMS:
The overall aim of this study is to investigate the impact of chronic migraine has
on rs-functional connectivity, and if treatment, such as the repetitive inhibition of the
SPG, can help to modulate the dysfunctional networks. Additionally, we aim to
determine if there is a distinct pattern of altered functional connectivity associated with
medication overuse headache.
Specific Aim 1: To assess differential patterns of network connectivity in specific
intrinsic resting state networks between chronic migraine patients, both with medication
overuse headache and without medication overuse headache, to healthy controls. This
aim will be tested by examining the differences in the DMN, TPN, SN, and ECN when
comparing CM patients to controls. We hypothesize that the chronic migraine population,
both with and without medication overuse headache, will have an overall decrease in
their network connectivity, for all networks examined, when compared to controls.
Specific Aim 2: To determine differences in predefined intrinsic functional
networks in the chronic migraine population based on the presence or absence of
medication overuse headache. To test this aim, we will directly compare the functional
connectivity difference between CM with MOH and CM without MOH as measured
using the intranetwork connections within the DMN, TPN, SN, and ECN. We hypothesize
that there will be differences in the intranetwork connections between CM with MOH and
CM without MOH due to the nature of their disorder.
Specific Aim 3: To evaluate the effect of Sphenopalatine ganglion blockade in
chronic migraine patients by determining if this treatment can normalize patterns of
resting state functional connectivity within the networks discussed above. This will be
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accomplished by comparing pretreatment resting state data with 30-minute post treatment
and 6-week post treatment resting state data, specifically in the DMN, TPN, SN, and
ECN. Additionally, clinical and behavioral scores will also be compared pre and post
treatment. We hypothesize that after long-term, recurrent inhibition of the SPG in chronic
migraine, there will be an increase in overall resting state brain connectivity compared
to baseline.
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CHAPTER 2: METHODS
METHODS
2.1 INCLUSION/EXCLUSION CRITERIA:
All subjects enrolled were diagnosed with chronic migraine, either with or
without medication overuse headache, using the ICHD-III beta criteria (“Headache
Classification,” 2013). Subjects were excluded if they had contraindication for MRI,
neurological disorders other than migraine, history of hypertension, diabetes, or inability
to follow study protocol while completing questionnaires and assessments. Anxiety and
depression were not considered as exclusion criteria as these are common comorbid
conditions with chronic migraine. All healthy control (HC) participants were screened for
any previous history of chronic headache, migraine, any pain disorders, any prior history
of chronic illness, family history of migraine, or use of OTC or prescription pain
medication for more than 5 days per month.
The treatment group had the additional exclusion criteria of any previous SPG
treatment, inability to complete the SPG treatment within 6 weeks, or inability to follow
study protocol while completing questionnaires and assessments. Subjects were
instructed to not change prophylactic medication or dosage during their treatment.
2.2 CLINICAL PARAMETERS:
Data collected from each participant prior to MRI included basic demographics
and a detailed migraine history that included:(1) age of first migraine; (2) years with CM;
(3) Family History of Migraine; (4) Current medication; (5) Body Mass Index (BMI);
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(6) Headache Impact Test (HIT-6) (Shin et al., 2008); (7) Patient Health Questionnaire
(PHQ-9) (Seo & Park, 2015); (8) Allodynia Symptom Checklist (ASC)(Lipton et al.,
2008); (9) number of headache days in a month (moderate to severe); (10) Type and
Frequency of headache abortive medication.
The Hit-6 scale is a six-question test developed by headache experts to measure
the impact of a patient’s headache on their ability to function at work, school, home or in
social situations. Each question has the same set of responses each with a weighted value
on a 5 point Likert scale, with a higher total score indicating a greater impact. The
severity of impact can be determined by the score, which indicates little or no impact
(≤49), some impact (50-55), substantial impact (56-59), or severe impact ( ≥60) (Shin et
al., 2008; Seo & Park, 2015). This test has been found to be a reliable and valid tool for
determining the impact of headaches for episodic and chronic migraine (Shin et al.,
2008). The patient health questionnaire (PHQ-9) is a nine-question test to measure the
severity of a patient’s depression. A PHQ-9 score can indicate if depression is mild (5-9),
moderate (10-14), moderate-severe (15-19) or severe (≥20). As anxiety and depression
are common comorbidities of migraine, this tool is often used in conjunction with other
headache questionnaires and has been proven to be a reliable screening tool in episodic
and chronic migraine patients (Seo & Park, 2015). The Allodynia symptom checklist
(ASC) is a series of questions which quantifies the presence of cutaneous allodynia, a
pain that is provoked by stimulation of the skin which would not ordinarily produce pain
(Lipton et al., 2008). The ASC measures overall allodynia and has been tested to be
associated with cutaneous allodynia experienced in migraine population (Lipton et al.,
2008).
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2.3 MR IMAGING:
The first 10 participants (5 CM and 5 HC) were scanned using a 12-channel head
coil on a Siemens Magnetom Trio 3T scanner and the remaining participants (28 CM and
16 HC) were scanned using a 20-channel head coil and the upgraded Siemens Prisma 3T
scanner model (McCausland Center for Brain Imaging, Columbia, South Carolina). All
participants were scanned in the same room with the same lighting. Participants were
instructed to keep their eyes closed, stay awake, relax, and not focus on anything during
the scans.
The Siemens Trio scans consisted of a 6-minute high-resolution T1 weighted
magnetization-prepared rapid gradient echo (MP-RAGE) series (repetition time
[TR] = 2250 ms, echo time [TE] =4.15 ms, 192 slices, 50% slice gap, flip angle = 9°,
voxel size = 1.0 mm3, 256 mm2 Field of View [FOV], iPAT factor of 2, and using a
sagittal, ascending, single shot acquisition). The 15-minute functional imaging scans used
a T2* weighted BOLD contrast-sensitive sequence ([TR] = 1550 ms, [TE] = 34 ms, 42
slices, 20% slice gap, flip angle = 71°, voxel size = 2.5 mm3, 215 mm2 FOV, and using a
transversal, descending, interleaved acquisition).
After the scanner upgrade, all remaining participants were scanned with a 6minute high resolution T1 weighted magnetization-prepared rapid gradient echo (MPRAGE) series ([TR] = 2250 ms, [TE] =4.11 ms, 192 slices, 50% slice gap, flip angle 9°,
voxel size = 1.0 mm3, 256 mm2 FOV, iPAT factor of 2, and using a sagittal, ascending,
single shot acquisition). The 15-minute functional imaging used a T2* weighted BOLD
contrast-sensitive sequence ([TR] = 1100 ms, [TE] = 35ms, 56 slices, 20% slice gap, flip

21

angle = 72°, voxel size = 2.4 x. 2.4 x 2.0 mm3, 216 mm2 FOV, and using a transversal,
ascending, interleaved acquisition).
2.4 MRI PREPROCESSING:
MRI preprocessing was a multistep process carried out using a resting state
analysis pipeline script developed by Chris Rorden
(https://github.com/neurolabusc/nii_preprocess). First, each participant’s T1 weighted
anatomical image was tissue segmented and normalized to MNI space using the
Statistical Parametric Mapping 12 (SPM12) toolbox and the unified segmentationnormalization functions (Ashburner & Friston, 2005) with associated tissue probability
maps for each tissue type (i.e. gray matter, white matter, CSF). Next, each rfMRI session
for each participant was motion corrected to the mean rfMRI image using SPM’s
realignment functions. Then, the mean rfMRI from the motion correction stage was
coregistered to the participant’s T1 weighted image so that the normalization parameters
computed from the T1 could then be applied to the rfMRI data. The application of the
normalization parameters produced rfMRI datasets in standard MNI space. After
normalization of resting state images, a brain mask was generated from the normalized,
segmented T1 scan, and was used in the detrending stage to eliminate irrelevant voxels
from analysis. The detrending stage of preprocessing consisted of removing linear, cubic,
and quadratic signal noise in the rfMRI time series including the mean signal in white
matter and CSF, and the six motion parameters calculated during the motion correction
stage earlier (x, y, z, pitch, roll, and yaw). This noise information was removed from the
rfMRI data for each session before temporal filtering (Hallquist, Hwang, & Luna, 2013).
After detrending for noise, the functional images were smoothed using a 6mm FWHM
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Gaussian kernel. Lastly, each rfMRI session was bandpass filtered with a low pass
frequency threshold of 0.1Hz and a high pass frequency threshold of 0.01Hz (inspired by
the REST toolkit; Song et al., 2011). These low frequencies have been shown to be
related to spontaneous neural activity, and contain meaningful information related to a
brain region’s function (Logothetis et al., 2001; Lu et al., 2007).
Analyses of the resting state functional connectivity were completed using a
region of interest (ROI) based approach with our four preselected networks. Connectivity
atlases for each network were derived using spherical ROIs centered (15 mm diameter)
on the peak Montreal Neurological Institute (MNI) coordinates reported by Fox et al
(2005), for DMN, and Seeley et al (2007), for the ECN and SN. Exact MNI coordinates
for all areas used in the networks are listed in “Appendix A: Supplemental Methods”
(Table A.1).
2.5 STATISTICAL ANALYSIS:
Using the generated ROIs, functional connectivity matrices were created by
extracting the mean BOLD time course from each ROI in each network, and then Pearson
r correlation coefficients were calculated between each ROI and all other ROIs in the
same network. This method has been used in many functional connectivity studies (Baliki
et al., 2012; Chen et al., 2016; Schwedt et al., 2013). In all networks, all Pearson
correlation (r) coefficient values were Fischer’s Z transformed (to convert to a normal
distribution) to produce the “functional connectivity strengths” that are used in the
analysis. Comparison groups were formed to investigate the relationship between the
following groups: CM w/MOH vs HC, CM w/o MOH vs HC, and CM w/MOH vs CM
w/o MOH.

23

Differences in functional connectivity strengths between all the comparison
groups were investigated on three levels: Overall network connectivity strength, average
nodal connectivity strength, and intranetwork connectivity strength. The intranetwork
connectivity strengths is defined as the correlation coefficient (fisher Z transformed
Pearson r value) generated for each pair of nodes within the network investigated. The
average nodal connectivity strength is the average of all unique intranetwork connectivity
strengths for one particular node. To obtain the overall network connectivity, we
averaged the sum of each unique intranetwork connection within the network
investigated. For an example of how each one of these functional connectivity strengths
was obtained, please see figure 2.1.
When comparing a CM group (either with or without MOH) to their matched
group of healthy controls (abbreviated as CM vs CON), we used an one tailed, two
sampled t-test. When comparing between the CM groups (CM w/MOH vs CM w/o
MOH), a two tailed, two sampled t-test was used. Corrected p values of < 0.05 were
considered significant for overall network strength differences (CM vs CON), average
nodal connectivity strength difference (CM vs CON), and intranetwork connection
strength differences (CM w/MOH vs CM w/o MOH). Corrected p values of < 0.01 were
considered significant for intranetwork connection strength differences (CM vs CON).
For the treatment group, the comparison groups used consisted of the time point
comparison from baseline to 30-minutes post treatment and baseline to 6-weeks post
treatment. The same statistical analysis method was utilized with the exception of the use
of a paired t-test.
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The intranetwork connectivity strengths:
AB, AD, AC, BC, BD, CD
The average (x̅) nodal connectivity strength:
Node A: x̅ A = (AB+AC+AD)/3
Node B: x̅ B = (AB+BC+BD)/3
Node C: x̅ C = (AC+BC+CD)/3
Node D: x̅ D = (AD+BD+CD)/3
The overall network connective strength:
Network ABCD = (AB + AD + AC + BC+ BD +CD)/6

FIGURE 2.1: Example network ABCD.

A one-tailed t-test was used for the overall network differences and difference in nodal
connectivity strength, whereas, a two-tailed t-test was used for intranetwork connection
strength differences. Corrected p values of < 0.05 were considered significant for all
statistical tests in the treatment group.
All statistical tests were conducted using permutation thresholding (10,000
permutations) to control for multiple comparisons (Winkler et al., 2014). Scanner type
was added as a nuisance variable to the GLM analyses, using the Freedman-Lane
approach, to account for any variance caused by two different scanner types (Freedman &
Lane, 1983).
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2.6 CLINICAL CORRELATIONS:
To assess associations between functional connectivity strength (overall and
intranetwork) and clinical parameters, Pearson correlations were conducted between the
functional connection strengths and several clinical parameters including depression and
anxiety scores (PHQ-9), headache severity (HIT-6), and Allodynia (ASC). Correlations
between functional connection strength and clinical characteristics (i.e. years with
migraine, years with CM, number of moderate to severe headache per month) were also
calculated. Correlations with an uncorrected p ≤0.001 were considered significant.
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CHAPTER 3:

CHRONIC MIGRAINE VS CONTROLS - RESULTS

CHRONIC MIGRAINE VS CONTROLS - RESULTS
3.1 STUDY PARTICIPANTS:
A total of 33 subjects with Chronic Migraine were enrolled into the study. A
total of 4 participants were excluded for the following reasons: motion artifact (n=1),
incidental finding (n=2), and delayed reporting of comorbid pain condition (n=1). All
Chronic Migraine participants were separated into two groups based on the presence of
medication overuse headache (MOH) as defined by the ICHD 3. These two group were:
Chronic Migraine with MOH (CM w/ MOH) and Chronic Migraine without MOH (CM
w/o MOH). Amongst the healthy control (HC) subjects (n=21) average age was 37 ± 11
years and all 21 subjects were female. Of the control 2 subjects were excluded for the
following reasons: motion artifact (n=1) and incidental findings (n=1). From the pool of
19 HC, a sample of 16 and 14 age and gender matched controls were selected for the
CM w/ MOH and CM w/o MOH groups, respectively. Individual characteristics for each
group are summarized in Table 3.1.
3.2 OVERALL NETWORK CONNECTIVITY:
Network strength averages for each chronic migraine group were compared to a
subset of age and gender matched healthy controls to reveal if there is a statistically
significant difference between each comparison group and their matched controls for the
DMN, TPN, SN, and ECN. For all comparison groups, DMN, SN, and ECN averages
were all significantly different from their matched control group (Table 3.2).
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TABLE 3.1: Demographic and clinical features of subjects based on CM subgroup.
Demographics:

CM w MOH

CM w/o MOH

HC

16

13

19

Age

39 ± 14

39 ± 12

37 ± 11

BMI

26 ± 6

31 ± 4

26 ± 5

10 Caucasian
6 African American

10 Caucasian
3 African American

12 Caucasian
7 African American

n

Race/Ethnicity
Clinical Features:

CM w MOH

CM w/o MOH

p-value

21 ± 7

15 ± 5

0.005*

Cranial Autonomic Symptoms

n=8

n=2

n/a

Family History (1st degree)

n=13

n=7

n/a

History of Migraine (years)

21 ± 13

20 ± 13

0.371

History of CM (years)

2±1

3±3

0.135

Hit-6 Score

67 ± 3

64 ± 4

0.03*

PHQ-9 Score

10 ± 6

5±3

0.006*

Allodynia (ASC) Score

6±3

5±6

0.22

Mod/Severe HA days

*significant

TABLE 3.2: Overall network connectivity strength and significance value for each
comparison group.
Comparison Group (Avg± SD)

DMN

TPN

SN

ECN

CM with MOH

0.51 ± 0.16

0.19 ± 0.17

0.05 ± 0.13

0.03 ± 0.09

Matched Control

0.61 ± 0.15

0.28 ± 0.13

0.14 ± 0.10

0.13 ± 0.08

0.029*

0.089

0.023*

0.003*

CM w/o MOH

0.50 ± 0.17

0.20 ± 0.16

0.07 ± 0.11

0.06 ± 0.07

Matched Control

0.64 ± 0.13

0.27 ± 0.14

0.15 ± 0.11

0.14 ± 0.08

p-value

0.016*

0.096

0.016*

0.015*

CM w/MOH vs CM w/o MOH**

0.756

0.568

0.812

0.835

p-value

*significant; **two-tailed t-test
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3.3 AVERAGE NODAL CONNECTIVITY:
Comparison of the average nodal connectivity strengths between CM groups to
age/gender matched controls revealed multiple significant individual node differences.
Some of the nodes are similar between the two groups and some are unique to each
group (Table 3.3). A list of all the significant average nodal strength, along with
averages, standard deviations, and p values for each group, are listed in “Appendix B:
Supplemental Results” (Table B.1).
The average nodal connectivity strength for left orbital frontal insula (SN:
p=0.057), right superior temporal (SN: p=0.057), and right DLPFC (ECN: p=0.052)
were borderline significant for the MOH vs control comparison, whereas, the left
DLPFC (ECN: p=0.052) was borderline significant for the CM w/o MOH vs control
comparison. For these four nodes, their counterparts in the opposite comparison group
were significant, therefore, making assumptions about these four nodes as delineating
differences between CM w/MOH and CM w/o MOH may not be appropriate. For the
purposes of this study, these four nodes will not be considered different between CM
w/MOH and CM w/o MOH groups.
3.4 INTRANETWORK CONNECTIVITY:
Comparison of the individual intranetwork connections for each comparison
group revealed multiple significantly differed intranetwork node-to-node connections. All
significant intranetwork connections were lower in CM patients when compared to
controls. A detailed list of all the significant intranetwork connection, along with
averages, standard deviations and p values for each group, are listed in “Appendix B:
Supplemental Results” (Table B.2).
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TABLE 3.3: Significant differences in average nodal connectivity strength for each
comparison group.
DMN
TPN
SN
Both CM groups (with and without MOH) vs matched controls
Left Lateral Parietal Left FEF Bilateral Ventral StriatumPallidum
Bilateral SN/VTA
Bilateral Hypothalamus
Bilateral Orbital Frontal Insula*
Right Superior Temporal*
CM w/MOH vs matched controls only
Right Lateral Parietal
Left Frontal Pole
Medial Prefrontal
Bilateral DLPFC
Right VLPFC
Bilateral Supramarginal Gyrus
Left SMA/preSMA

ECN
Left Lateral Parietal
Right Inferior Frontal
Gyrus
Bilateral VLPFC
Right DLPFC/FEF
Bilateral DLPFC*
Left Anterior Thalamus*
Dorsomedial PFC
Left Orbital Frontal Insula
Right Anterior Thalamus
Right Dorsal Caudate
Right Ventromedial
Caudate

CM w/o MOH vs matched controls only
Precuneus/PCC
Bilateral Subcallosal Area
Left DLPFC/FEF
Bilateral ACC
Left Temporal Pole
* Borderline significant in other comparison group (see section 3.3)
NOTE: Statistical differences determined using a one tailed t-test with a threshold of p<0.05

The only significant intranetwork connection in the DMN (left lateral parietal to
precuneus/PCC, p=0.003) and TPN (left FEF to right intraparietal sulcus, p=0.006) was
lower in CM without MOH patients when compared to the matched controls. In the SN,
three intranetwork connections (Right DLPFC to right supramarginal gyrus and right
VLPFC; and right VLPFC to right SMA/preSMA) were significantly lower in both CM
groups when compared to controls. In the ECN, two intranetwork connections (left
DLPFC/FEF to DMPFC, and left anterior thalamus to right VLPFC) were significantly
different in both CM groups when compared to controls. The remaining significant
connections were unique to each comparison group (CM w/MOH vs controls, or CM w/o
MOH vs controls). All significantly different intranetwork connections and average nodal
strengths in the SN and ECN are displayed in Figure 3.1 and 3.2, respectively.
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FIGURE 3.1: Significant intranetwork connectivity and average nodal difference in SN between CM w/MOH vs controls (left) and
CM w/o MOH vs controls (right). Colored bar and line represents a significant nodal and intranetwork connectivity difference
(respectively) between the CM groups vs their matched controls. Green represents a unique difference to that comparison group and
blue represents a shared difference in both comparison groups. Images were generated using the Matlab application “Circro”
(https://github.com/bonilhamusclab/circro).
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FIGURE 3.2: Significant intranetwork connectivity difference in ECN between CM w/MOH vs controls (left) and CM w/o MOH vs
controls (right). Colored bar and line represents a significant nodal and intranetwork connectivity difference (respectively) between
the CM groups vs their matched controls. Green represents a unique difference to that comparison group and blue represents a shared
difference in both comparison groups. Images were generated using the Matlab application “Circro”
(https://github.com/bonilhamusclab/circro).

3.5 COMPARISON BETWEEN CM GROUPS:
When comparing CM with MOH and CM w/o MOH, there was no statistically
significant difference for overall network strength for DMN (p=0.76), TPN (p=0.57), SN
(p=0.81), and ECN (p=0.84). Additionally, no average nodal strengths appeared to be
significantly different between these two groups. When examining intranetwork
connectivity differences, there were 8 intranetwork connections in the SN and 3
intranetwork connections in the ECN that were significantly different. These
intranetwork differences are summarized in Table 3.4 and visualized in Figure 3.3.
3.6 CLINICAL CORRELATIONS:
Of the clinical features, only the number of moderate to severe headache days
(Mod/Severe HA days), Hit-6 scores, and PHQ-9 scores was significantly different
between the CM w/MOH group and CM w/o MOH group, and therefore the clinical
features compared separately for each CM group. Years with migraine, years with
chronic migraine, and allodynia (ASC score) were not statically different when
comparing CM w/MOH vs CM w/o MOH, therefore all correlations involving these
variables were conducted using the full CM population. The relationship between
medication use and intranetwork connections were only evaluated in the CM w/MOH
group, as there were only a few individuals in the CM w/o MOH who used any
medication. There were no significant intranetwork connections in the DMN that
correlated to any clinical parameter. These correlations are summarized in Table 3.5.
Connections that are significantly different between two group are marked by an asterisk
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TABLE 3.4: Significant differences of intranetwork connections when comparing CM
w/MOH vs CM w/o MOH.
CM w/MOH CM w/o MOH
p(Avg ± SD)
(Avg ± SD)
value

Salience Network
CM w/MOH < CM w/o MOH
Left Frontal Pole x Right Orbital Frontal insula

0.57 ± 0.26

0.81 ± 0.12

0.018

Left Ventral Striatum/Pallidum x Left SMA/preSMA*

0.26 ± 0.15

0.44 ± 0.19

0.026

Left DLPFC x Left Ventral Striatum/Pallidum*

0.16 ± 0.15

0.37 ± 0.16

0.009

Left DLPFC x Right Ventral Striatum/Pallidum*
Left DLPFC x Left Dorsal ACC*

0.12 ± 0.15
0.14 ± 0.16

0.32 ± 0.16
0.36 ± 0.21

0.010
0.015

Left DLPFC x Right Dorsal ACC

0.44 ± 0.27

0.64 ± 0.14

0.036

Right SN/VTA x Paracingulate

0.10 ± 0.15

0.04 ± 0.10

0.043

Right Subcallosal Area x Left Subcallosal Area**

0.82 ± 0.31

0.55 ± 0.24

0.044

0.08 ± 0.15

0.24 ± 0.22

0.040

0.41± 0.24

0.22 ± 0.27

0.007

0.21 ± 0.32

0.00 ± 0.29

0.043

CM w/MOH > CM w/o MOH

Executive Control Network
CM w/MOH < CM w/o MOH
Right Inferior Frontal Gyrus x Left DLPFC*
CM w/MOH > CM w/o MOH
Left DLPFC/FEF x Right VLPFC
Left DLPFC/FEF x Right DLPFC

*Intranetwork connection was found to be significant in MOH vs Control group
**Intranetwork connection was found to be significant in nonMOH vs Control group
NOTE: Statistical differences determined using a two-tailed t-test with a threshold of p<0.05

TABLE 3.5: Statically significant correlations between clinical features and intranetwork
connectivity strength.
Correlated Clinical Measure
Network
Years with CM
Left Subcallosal Area x Left Frontal Pole*
SN
Allodynia Score
Right Hypothalamus x Left Dorsal ACC
SN
HIT-6 Score
Right SMA/PreSMA x Left PAG
SN
Number of Triptans/month (MOH group only)
Right SN/VTA x Left Orbital Frontal Insula
SN
Right SN/VTA x Right Subcallosal Area
SN
Left DLPFC/FEF x Right DLPFC
ECN
Right Inferior Temporal x DMPFC
ECN
*significantly different in one of the comparison groups
Note: significance threshold was p≤0.001
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CM Group

r-value p-value

CM (all)

-0.60

0.001

CM (all)

0.60

0.001

CM w/MOH

0.82

<0.001

CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH

-0.82
0.86
-0.77
0.77

<0.001
<0.001
0.001
0.001
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FIGURE 3.3: Significant intranetwork connectivity difference between CM w/MOH and CM w/o MOH in the SN (left) and ECN
(right). Colored line represents a intranetwork connectivity difference between the CM w/MOH vs CM w/o MOH. Green represents a
that the intranetwork connection was lower in CM w/o MOH patients (CM w/MOH > CM w/o MOH) and blue represents a that the
intranetwork connection was lower in CM w/MOH patients (CM w/MOH < CM w/o MOH). Images were generated using the Matlab
application “Circro” (https://github.com/bonilhamusclab/circro).
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TREATMENT STUDY RESULTS

TREATMENT STUDY RESULTS
4.1 STUDY PARTICIPANTS:
An age and gender matched subset of 14 subject were recruited into the treatment
group. Four subjects were excluded due to the following reasons: motion artifact (n=1),
scanner error (n=2), and unreported comorbid pain condition (n=1). Each subject
underwent a series of MRI scans at three time points: immediately before their first SPG
treatment, 30 minutes after their first SPG treatment, and 30 minutes after their last SPG
treatment (6-weeks post treatment). Two subjects were missing one of their three scans
(one was missing 30-minute post treatment scan; another was missing 6-week scan) but
they were still included in comparisons involving the scan sets that were completed.
Individual characteristics for the treatment group are summarized in Table 4.1.
4.2 OVERALL NETWORK CONNECTIVITY CHANGES:
Each individual’s before treatment network strength averages were compared to
their network strength averages at two other two time points: 30-minutes and 6-week post
treatment. Separate comparisons were made for the following networks: DMN, TPN, SN,
and ECN. When comparing before treatment with 30-minutes post treatment, only the
ECN showed a significant increase in overall network connectivity strength (p = 0.004).
When comparing before treatment with 6-week post treatment, both the DMN and ECN
showed a significant increase in overall network connectivity strength (DMN: p = 0.046;
ECN: p = 0.003). Network strength averages and p values are summarized in Table 4.2.
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TABLE 4.1: Demographic and clinical features of subject in treatment group.
Demographics:
n

Clinical Features:

10

Age

43 ± 13

BMI

28 ± 8

Gender

21 ± 7

History of CM (years)

2±1

Family History (1st degree)

10 females

n=8 (1 uk)

History of Migraine (years) 26 ± 12

8 Caucasian
2 African American

Race/Ethnicity

Mod/Severe HA days

Quality of Life Scales:

Cranial Autonomic Symptoms n=5

Before TX

After TX

p-value

Hit-6 Score

66 ± 3

60 ± 4

<0.01*

PHQ-9 Score

13 ± 6

6±4

0.008*

Allodynia (ASC) Score

6±3

5±4

0.238

Number Mod/Severe HA Days

21 ± 7

11 ± 6

<0.01*

*significant

TABLE 4.2: Overall network connectivity strengths and significance value when
comparing Baseline to 30-minute and 6 weeks post first treatment.
Baseline vs 30-minutes
(Avg ± SD)

DMN

TPN

SN

ECN

Before Treatment

0.56 ± 0.14

0.11 ± 0.11

0.01 ± 0.11

0.01 ± 0.08

30-min Post Treatment

0.62 ± 0.19

0.06 ± 0.10

0.00 ± 0.07

0.07 ± 0.05

0.404

0.230

0.203

0.004*

Before Treatment

0.55 ± 0.15

0.11 ± 0.11

-0.01 ± 0.10

0.00 ± 0.08

6-weeks Post Treatment

0.59 ± 0.14

0.14 ± 0.13

0.01 ± 0.12

0.03 ± 0.09

0.046*

0.087

0.205

0.003*

p-value
Baseline vs 6 weeks
(Avg ± SD)

p-value
*significant
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4.3 AVERAGE NODAL CONNECTIVITY CHANGES:
When comparing baseline average nodal strength to 30-minute post treatment
average nodal strength, 2 nodes in the SN and 8 nodes in the ECN are significantly
increased. When comparing baseline average nodal strength to 6-week post treatment
average nodal strength, 2 nodes in the DMN, 2 nodes in the Salience, and 4 nodes in the
ECN were significantly increased. No changes were observed in the TPN in either time
point comparison. Significant average nodal differences, when comparing baseline to 30
minute and 6 weeks post treatment, are listed in Table 4.3 and illustrated in Figure 4.1,
4.2, and 4.3. A detailed list of all the significant average nodal strength for each time
point comparison is located in “Appendix B: Supplemental Results” (Table B.3).
4.4 INTRANETWORK CONNECTIVITY CHANGES:
Comparison of the individual intranetwork connections for each time point
comparison revealed multiple significantly different intranetwork connectivity strengths
(Table 4.3). No changes were observed in the TPN in either time point comparison and in
the DMN when comparing baseline to 6 weeks post treatment. All significant
intranetwork connections increased after treatment, except for one in the SN (Left
Superior Temporal to Right Supramarginal Gyrus). This one intranetwork connection
was non-significantly lower in Controls when comparing CM to controls, which may
reflect a normalization after treatment. Significantly different intranetwork connections
for DMN, SN and ECN are seen in Figure 4.1, 4.2, and 4.3, respectively. A detailed list
of all the significant intranetwork connectivity differences each time point comparison is
located in “Appendix B: Supplemental Results” (Table B.4).
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TABLE 4.3: Significantly different nodal connectivity strengths in a network when
comparing baseline to 30-minute and 6 weeks post first treatment.
Network
DMN
SN

ECN

Baseline vs 30 minutes
None
Left Frontal Pole
Right SN/VTA
Bilateral VLPFC
Bilateral DLPFC/FEF
Bilateral DLPFC
Left Anterior Thalamus
Right Lateral Parietal

Baseline vs 6 Weeks
Right Lateral Parietal
Precuneus/PCC
Left Frontal Pole
Right SN/VTA
Left VLPFC
Bilateral DLPFC/FEF
Left DLPFC

NOTE: Statistical differences determined using a one-tailed t-test with a threshold of p<0.05

FIGURE 4.1: Significant differences in the DMN when comparing baseline to 6 weeks.
Green lines and bars represent an improvement of intranetwork connectivity strength and
average nodal strength after treatment.
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40
FIGURE 4.2: Significant intranetwork connectivity and average nodal difference in the SN when comparing baseline to 30-minute
(left) and 6 weeks post first treatment (right). Green lines and bars represent an improvement of intranetwork connectivity strength and
average nodal strength after treatment. The red line represents the one intranetwork connectivity strength that decreased after
treatment (see section 4.4). Dashed line and bolded text represents similar improvements that are seen when comparing both time
points. Images were generated using the Matlab application “Circro” (https://github.com/bonilhamusclab/circro).
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FIGURE 4.3: Significant intranetwork connectivity and average nodal difference in the ECN when comparing baseline to 30-minute
(left) and 6 weeks post first treatment (right). Green lines and bars represent an improvement of intranetwork connectivity strength and
average nodal strength after treatment. Dashed line and bolded text represents similar improvements that are seen when comparing
both time points. Images were generated using the Matlab application “Circro” (https://github.com/bonilhamusclab/circro).

4.5 CLINICAL CORRELATIONS WITH NETWORK CHANGES:
When evaluating the relationship between improvements (delta) in clinical
measures (i.e number of moderate to severe headache days/month, and quality of life
scores) and changes in intranetwork functional connectivity, after 6 weeks of SPG
treatment, there appears to be several relationships between improvements of these
clinical measures and increased intranetwork functional connectivity (Table 4.4). A
reduction of moderate to severe headache (HA) days and improved PHQ-9 scores were
correlated with increased intranetwork functional connectivity in the SN. Improved HIT6 scores were correlated to increased functional connectivity in the ECN. Only one
intranetwork connection (left subcallosal area to left SMA/preSMA) had a negative
correlation, indicating that a reduction to the number of moderate to severe headaches
days after treatment is related to a weaker intranetwork functional connectivity between
those regions in the SN.
TABLE 4.4: Statically significant correlations between changes in clinical measures
(delta) and changes in intranetwork connectivity strength after 6 weeks of treatment.
Network

r-value

p-value

Left Subcallosal Area x Left SMA/preSMA

SN

-0.86

0.001

Left Frontal Pole x Left Orbital Frontal Insula

SN

0.87

0.001

Left Ventral Striatum/Pallidum x Left DLPFC

SN

0.86

0.001

Right DLPFC x Right Dorsal ACC

SN

0.93

<0.001

Right SN/VTA Right DLPFC

SN

0.90

<0.001

Right SN/VTA x Right Hypothalamus

SN

0.87

0.001

Right Lateral Parietal x Left VLPFC

ECN

0.87

0.001

Right DLPFC/FEF x Left VLPFC*
Delta PHQ-9

ECN

0.87

0.001

0.87

0.001

Delta Number of Moderate to Severe HA Days

Delta Hit-6 Score

SN
Right Ventral Striatum/Pallidum x Right DLPFC
*connection was significantly different at one of the time points
Note: significance threshold was p≤0.001
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CHAPTER 5: DISCUSSION
DISCUSSION
5.1 OVERALL CHANGES IN FUNCTIONAL NETWORKS:
For both CM with and without MOH, we report a significant decrease in overall
network strength in the DMN, SN, and ECN when compared to healthy controls. This
relative decrease in overall network strength can be interpreted as a dysregulation of one
or more regions within each respective network. Dysfunctional intrinsic resting-state
networks have previously been observed in chronic pain conditions. However, it is very
difficult to determine if changes in these brain networks causal or consequential to
having chronic pain (Baliki, Baria, & Apkarian, 2011; Baliki et al., 2014; Malinen et al.,
2010; Napadow et al., 2010; Napadow et al., 2012).
It is important to point out that “dysfunction” in, or “disruption” of overall
network/nodal strengths can occur due to either the strengthening or weakening of
existing intranetwork functional connections. Both changes would result in the overall
degradation of overall network coherence. Therefore, our methods do not allow us to
interpret an increase or decrease of network activity, so for the purposes of this
discussion we will use the term “increased” to refer to greater functional coherence in
experimental as compared to control groups, and “decreased” to refer to lesser functional
coherence in experimental as compared to control groups.
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When comparing each CM group to a set of age matched controls, we observed
similar patterns of impaired connectivity for both groups. Similarly, impaired regions
(“nodes”) of connectivity, within their respective networks, involve areas of the
limbic/basal ganglia (hypothalamus, anterior thalamus, SN/VTA, ventral
striatum/pallidum), frontal cortex (DLPFC, VLPFC, FEF, insula, inferior frontal gyrus)
and pain processing/sensory areas (left lateral parietal and right superior temporal).
5.2 DYSFUNCTIONAL FC IN CM WITH AND WITHOUT MOH:
One of this study’s aim was to investigate the similarities and differences between
intrinsic brain networks in CM patients with MOH and without MOH. By examining our
a priori networks of interest (DMN, TPN, SN, and ECN), we could determine specific
patterns of neuromodulation associated with the pathophysiology of these two types of
chronic migraine. To the best of our knowledge, no resting-state functional connectivity
study has made direct comparisons between CM w/MOH and CM w/o MOH patients.
As both chronic migraine groups exhibited an overall dysfunction to these
networks, as well as several similarly disrupted nodes within a network, it has proven
difficult to determine the difference between these two groups based on just those
results. However, by examining the intranetwork connectivity within a given network,
we believe that possible underlying systems (“subnetworks”) will help shed light on the
differences between CM with and without MOH. Some of these subnetworks include
fronto-striatal and cortical-thalamic systems, such as the mesocorticolimbic
dopaminergic system and the cortico-basal ganglia-thalamic system. As these
subnetworks play a role in the SN and ECN, it may be necessary to break apart these
two networks to see if there are disruptions to these smaller, embedded systems, which
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may ultimately cause widespread network dysfunctions. Due to the nature of this study,
we cannot examine causality within these subnetworks. However, for the purposes of
this discussion, we will use these subnetworks to hypothesize possible mechanisms that
cause the chronification of migraine, and how medication overuse plays into those
mechanisms.
The mesocorticolimbic dopaminergic pathway is a dopamine distribution system
that plays important roles in reward, emotional salience, cognitive control, and
motivation (Wise, 2009; Laviolette, Nadar, & van der Kooy, 2002). Starting in the VTA,
this system branches off into two smaller ones based on where the VTA transmits
dopamine to: the mesocortical system (SN/VTA, ACC, OFC, VMPFC, and DLPFC) and
mesolimbic system (SN/VTA, ventral pallidum/nucleus accumbens) (Bowers, Chen, &
Bonci, 2010; Wise, 2009; Everitt et al., 2007; Draganski et al., 2008). With the
exception of VMPFC, all regions of the mesocorticolimbic dopamine pathways are
present in the salience network and alterations to this pathway can possibly provide a
tool for evaluating chronic migraine, both with and without MOH.
As the basal ganglion has been postulated to play an important role in chronic
pain, other systems partially comprised of the basal ganglia may be important to
investigate (Borsook et al., 2010; Wood et al., 2007). The cortico-basal ganglia-thalamic
system (sometimes referred to as “striato-thalamo-orbitofrontal” and “fronto–striato–
subthalamic–pallidal”) is another subnetwork based around the basal ganglion and its
connection to cortical and thalamic regions (Jahanshahi et al., 2015). This pathway is
also interconnected with DLPFC, insula, and ACC and includes glutamatergic
(excitatory) innervations of the PFC to amygdala, nucleus accumbens and VTA
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(Adinoff, 2004). It also includes innervations to the mesocortical dopaminergic systems
(Jahanshahi et al., 2015; Gardner & Ashby, 2000).
This system is believed to have three distinct functions, each involving some of
the intranetwork connection listed above. These three functions are motor (motor cortexbasal ganglia-thalamus), associative/cognitive (frontal lobe-caudate-thalamus), and
emotion/limbic (ACC-basal ganglia-thalamus) (Jahanshahi et al., 2015). These
functionally divided pathways can be seen in both the SN (emotional/limbic) and ECN
(motor and associated/cognitive), each involved with different regions of the basal
ganglia (ventral striatum and dorsal striatum/caudate, respectively) (Haber, 2003).
5.3 FC DYSFUNCTIONS IN CM WITH MOH PATIENTS:
The constant negative reinforcement of taking analgesic medication may
contribute to a development of addictive/compulsive traits. This reinforcement has led
previous researchers to hypothesize that addiction may play an important role in MOH
pathophysiology (Lundqvist et al., 2010; Sances et al., 2010; Di Lorenzo et al., 2007; Di
Lorenzo et al., 2009; Navratilova et al., 2012). Evidence of addiction related
neuromodulation is observed in our MOH subgroup, with the unique patterns of
dysfunctions seen in the SN’s mesocortical dopaminergic system and the ECN’s corticobasal ganglia- thalamic systems. Metabolic changes to both of these subnetworks are
believed to contribute to addiction and compulsive drug seeking behavior (Luscher &
Malenka, 2011; Asensio et al., 2010; Paulus et al., 2002; Goldstein et al., 2007; Bolla et
al., 2003; Ersche & Sahakian, 2007; de Greck et al.,2009; Wrase et al.,2007; Zhang et al.,
2009; London et al., 2000; Volkow & Fowler, 2000; Volkow, Fowler, & Wang GJ, 2004;
Verdejo-García et al., 2006).
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Specifically, within the SN, dysfunctional connectivity was observed between
regions of the mesocortical dopaminergic system (DLPFC, OFC, ACC) and in between
frontal lobe regions and other limbic structures. Within the ECN, unique patterns of
dysfunctions were seen in regions involved with the “associative/cognitive” function of
the cortico-basal ganglia-thalamic network, such as the orbital frontal insula,
dorsomedial PFC, anterior thalamus, right dorsal and ventromedial caudate. Most
notably, disruptions between the DLPFC and bilateral anterior thalamus were unique to
CM with MOH patients. Dysfunction to these regions coincides with altered GM
volume reported in previous VBM studies on MOH patients (Chanraud et al., 2014;
Riederer et al., 2012; Lai et al., 2016).
As compared to the CM without MOH cohort, MOH patients had more
widespread disruptions in frontal lobe connectivity to other regions the SN (frontal pole,
DLPFC, VLPFC, and SMA/preSMA) and ECN (inferior frontal gyrus, DLPFC, and
VLPFC). This finding may also be explained by previous addiction studies, as
impairments in regions of the frontal cortex are believed to result in increased craving
and inhibition of cognitive control in drug abusers (Goldstein & Volkow, 2002;
Goldstein et al., 2004; Goldstein et al., 2007; Yang et al., 2009).
5.4 FC DYSFUNCTIONS IN CM WITHOUT MOH PATIENTS:
CM has been hypothesized to be caused by central sensitization, which is a nonassociative learned response after repeated administration of a noxious stimulation,
resulting in the amplification of the response (Woolf, 2011; Filatova, Latysheva &
Kurenkov, 2008; Bendtsen, 2000; Ashina et al., 2006; Zaman et al., 2015). The
increased connectivity of the basal ganglia to regions involved in integrative pain
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processing (such as the insula, OFC, ACC, PCC, and temporal pole) in migraine may
have contributed to a learned sensitization (Yuan et al., 2013; Malaki et al., 2011). It is
not clear which neural mechanism may be the cause of this hypersensitivity to pain,
however, some research has suggested that chronic pain is a result of dysfunctional
endogenous inhibition of pain (Lewis et al., 2012; Granovsky & Yarnitsky, 2013;
Granovsky, 2013; Ablin & Buskila, 2013; Bouwense et al., 2013; Williams et al., 2013).
The disinhibition of pain may manifest in the SN in the form of impaired habituation
mechanisms, and in the ECN, in the lack of cognitive modulation of pain.
Two studies in episodic migraine do suggest that habituation, or lack thereof,
may be a factor in migraine (Coppola et al., 2013; Stankewitz, Schulz, & May, 2013). In
fact, there are many chronic pain studies that suggest that lack of habituation of
continuous painful stimuli could play a role in the chronification of pain, however, it is
not clear if this is a cause or effect of chronic pain (Bingel et al., 2007; Mirci & Savas
2002; Flor, Diers, & Birbaumer, 2004; Peters, Schmidt, & Van den Hout, 1989;
Cecchini et al., 2003; Valerian et al., 2003).
In our study, one of the most intriguing findings is the prominent dysfunction of
the SN’s bilateral subcallosal area in CM without MOH. This dysfunction is not found
in the CM with MOH subgroup, which upon review of the raw data, shows that the
MOH group’s network strengths involving the subcallosal area is comparable to that of
controls. The subcallosal area, also known in literature as the parolfactory or
sublenticular extended amygdala, is a region of the frontal lobe that is connected to areas
in the vlPFC, OFC, and ACC areas (Mark et al., 1994). The posterior region of the
subcallosal area also overlaps with the anterior nucleus accumbens (NAc), part of the
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ventral striatum (Blood & Zatorre, 2001; Gruber, Hussain, & O'Donnell, 2009). Within
the salience network, the subcallosal area has been functionally linked to areas, such as
the ventral striatum/nucleus accumbens, dorsomedial thalamus, hypothalamus, and
periaqueductal gray area. (JohansenBerg et al., 2008; Ongur and Price, 2000; Ongur,
Ferry, & Price, 2003; Drevets, Ongur, & Price, 1998)
The subcallosal area has been reported in chronic tinnitus models as a “hub” that
links the limbic-affective systems with thalamo-cortical perceptual systems. In these
models, the subcallosal area, with the help of the interconnected areas of vmPFC and
NAc, acts as an inhibitory gating mechanism (a “switch”), which, when “turned on”,
will signal to the brain stem/thalamus to habituate the auditory signal. However, when
this area fails to habituate the signal, the auditory signal is relayed from the thalamus to
the sensory areas resulting in chronic tinnitus (Rauschecker, Leaver, & Muhlau, 2010).
The author of this study hypothesized that the cause of this dysfunction in the
subcallosal area was due to the constant hyperactivity of the nucleus accumbens, which
induced excitotoxicity in this region (Rauschecker, Leaver, & Muhlau, 2010). This
hypothesis may be plausible, however, there is not enough research on this topic to
determine it this explanation could extend to migraine.
The author of this chronic tinnitus model also suggest that this same model could
be translated to chronic pain (Rauschecker, Leaver, & Muhlau, 2010). Even though the
subcallosal area was not directly mentioned, previous chronic pain studies have already
suggested that modulation between the NAc and mPFC is a possible cause of pain
chronification (Bingel & Tracey, 2008; Becerra et al., 2001; Kuchinad et al., 2007;
Schweinhardt et al., 2009; Baliki et al., 2006; Baliki et al., 2010; Baliki et al., 2012;

49

Hashmi et al., 2013). In chronic migraine, the dysfunction of the subcallosal areas could
contribute to central sensitization; that is, hyperalgesia is a result of the dysfunction in
this region's ability to inhibit the thalamus from relaying pain to sensory regions.
Chronic migraine could very well be a result of disinhibition of the thalamus due to the
dysfunctional gating mechanisms at the subcallosal area.
Our findings also indicated a possible role of the SN’s subcallosal areas in the
habituation of pain. To our knowledge, this is the first study to report a dysfunction of
the subcallosal area in chronic migraine. It is possible that this region only appears to be
dysfunctional within the confines of the SN, therefore it has not been observed in other
fMRI studies on CM.
5.5 CM WITH MOH VS CM WITHOUT MOH:
For both MOH and non MOH patients, the overall network strength of the DMN
appears to be lower than healthy controls. When you examine the individual nodes, both
groups appear to have a common decrease in connectivity between the left lateral
parietal area and other nodes within the DMN network. However, differences between
the two groups (when compared to controls) manifest as dysfunctionality of the right
lateral parietal and medial PFC, in the MOH patients, and precuneus/PCC, in the
nonMOH patients. Previous reports of decreased connectivity between left lateral
parietal and precuneus regions in chronic pain patients, is consistent with our findings
for the non MOH group, but not the MOH group (Glass et al., 2011). As there were no
significant differences between MOH and nonMOH patients when compared to each
other, it is hard to speculate if these differences in the DMN were caused by chronic
pain, the overuse of medication, or a combination of both.
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A more logical explanation to the observed impairment of the DMN is that its
relationship with the SN and ECN is consequentially causing a disruption to the DMN.
As the DMN is functionally coupled with the SN and ECN, it is possible that disruptions
to the DMN are a consequence of impaired SN and ECN (Gao & Lin, 2012; Deshpande,
Santhanam, & Hu, 2011; Seeley et al., 2007). Unfortunately, our methods did not
directly measure the relationship between DMN and the SN/ECN, therefor this is merely
speculative.
Within the SN, both CM groups presented with disruptions to the mesolimbic
dopaminergic pathways. In particular, similar disruptions were seen in connections
involving the basal ganglia. This is not surprising as the basal ganglia has a central role
in the mesolimbic system, and its functions include reinforcement learning, motivation,
and reward (Schultz, 1997; Houk & Adams, 1995; Graybiel, 1998). However, due to the
associations of chronic pain and addiction to alternate mesocorticolimbic dopamine
pathways, it cannot be assumed that similar disruption to these areas are cause by the
same pathophysiology (Luscher & Malenka, 2011; Asensio et al., 2010; Paulus et al.,
2002; Goldstein et al., 2007; Bolla et al., 2003; Ersche & Sahakian, 2007; de Greck et
al.,2009; Wrase et al.,2007; Zhang et al., 2009; Borsook et al., 2010; Wood et al., 2007).
Differences in the SN between the MOH and nonMOH groups are most
apparently in that widespread disruption of connections involving prefrontal regions and
the subcallosal area, respectively. When comparing MOH to nonMOH patients, the
intranetwork connections within the SN that were significantly lower in MOH patients
all included connections to the frontal lobe. As disruptions are present in non-MOH
patients in prefrontal regions of the ECN, but not the SN, it can be deduced that the
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addiction aspect of MOH may be causing additional dysfunctions of the mesocortical
system within the SN.
Additionally, when directly comparing the two groups, the intranetwork
connections between bilateral regions of the subcallosal area was more disrupted in
nonMOH patients. This was also observed when comparing the CM to controls, as
nonMOH patients mainly showed disrupted connectivity between the subcallosal area
and other regions of the SN, where MOH patients did not. It is curious that the
subcallosal area did not appear to be affected within the SN of the MOH group.
Assuming that MOH patients also develop chronic migraine as a result of dysfunctional
thalamic inhibition systems, proposed in the previous section, the impairment may be
located in a downstream location of the thalamic inhibition system. In other words, as
the subcallosal area is indirectly connected to the thalamus, it is possible that
impairments to this thalamic inhibition system may have occurred in one of the
pathways indirectly connecting the subcallosal area to the thalamus, such as the globus
pallidum or thalamic reticular nucleus (O’Donnell et al., 1997; Guillery & Sherman,
2002).
Another possible explanation for the preservation of this area comes from the
result of a recent study by Chen et al. (2016) comparing CM with MOH vs CM without
MO. In this study, the marginal division of the neostriatum, located on the caudal border
of the striatum and rostral edge of globus pallidus, was found to be affected in CM
without MOH, but not CM with MOH. The author of that study suspected that the use of
medication inhibited the modulatory function of the marginal division of the
neostriatum, which therefore protected that area and its connectivity (Chen et al., 2016).
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Perhaps a similar mechanism is responsible for somewhat “sparing” the subcallosal area
in MOH patients. However, in order to test this hypothesis, additional research on these
relay areas would be needed.
In regards to the ECN, the similar disruption of the frontal cortex may be a result
of an impaired downstream modulation of pain. The prefrontal cortex has long been
thought to play a key role in the cognitive modulation of pain, specifically with the ability
to initiate the downstream modulation of pain (Bingel & Tracey, 2008). Increased
activation of the frontal pole and VLPFC is related to an analgesic effect of pain, due to
the inhibition of functional connectivity between the thalamus and midbrain regions
(Lorenz, Minoshima, & Casey, 2003; Salomons et al., 2007; Wiech et al., 2006). The
DLPFC is often upregulated in chronic pain patients due to the increased use in the
descending modulation of pain. (Wager et al., 2004; Lorenz, Minoshima, & Casey, 2003;
Seminowicz et al., 2013) This constant activation of the DLPFC in chronic pain may
cause functional and anatomical neuromodulation evident by the decreased cortical
thickness observed in chronic pain conditions (Apkarian et al., 2004; Seminowicz et al.,
2011). Consequently, this neurodegeneration could have a negative impact on descending
pain modulation, thus contributing to a chronic pain state (Tracey & Mantyh, 2007). In
contrast to the SN, which may use frontal regions to determine the salience of the pain,
we posit that within the executive network, frontal regions of the brain are disrupted in
both CM groups is due to the consistent upregulation of the descending pain modulation
Taken together, we speculate that chronic migraine is the result of dysfunctional
inhibition mechanisms responsible for inhibiting the thalamus from relaying to pain
processing areas of the brain. This would possibly explain the neural mechanism behind
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the central sensitization hypothesis, in which the brain can no longer habituate to
innocuous stimuli resulting in frequent headaches/ migraine. We propose that there is a
similar mechanism at play in MOH patients, however, due to the overuse of medication,
this impairment may have manifested in a downstream location of the thalamic
inhibition system. Additionally, we postulate that the overuse of medication accelerates
the transformation of episodic migraine to chronic migraine due to the additional role of
negative reinforcement in pain relief (reward incentive). Compared to non MOH
patients, this increased salience of reward is apparent in the dysregulation of the
prefrontal regions/mesocorticolimbic system within the SN.
5.6 EFFECTS OF SPG TREATMENT ON FC:
After receiving 6 weeks of SPG block treatment, an overall improvement is seen
in both the ECN and the DMN. Though the ECN is also significantly improved 30
minutes after the first treatment, the additional restoration of the DMN at the 6 week
post first treatment shows promise that repetitive inhibition of the SPG helps normalize
functional connectivity. This is supported by evidence that the DMN and ECN are
functionally coupled with each other (Gao & Lin, 2012; Deshpande, Santhanam, & Hu,
2011; Seeley et al., 2007).
One of the most promising results is the 6-week post treatment connectivity
improvement of the precuneus/PCC region of the DMN. Specifically, its intranetwork
connectivity increased to right lateral parietal and medial PFC, relative to baseline
connectivity measures. Our baseline data mirror a previous resting-state functional
connectivity study in MOH patients which found lower functional connectivity between
precuneus to right lateral parietal and right mPFC in the DMN (Chanraud et al., 2014).
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Here, we show that these functional connections are not permanently disordered, rather,
they begin to normalize after six weeks of treatment. Additionally, in another MOH
study, hyperactivity in the precuneus/PCC region appeared to normalize after they
detoxified (Fumal et al., 2006). Unfortunately, it is unknown if the improvement from
the precuneus to mPFC is due to the improvement in depression scores, as this
connection has previously been reported as a “mediator” between pain severity and
depression scores (Schweinhardt et al., 2006).
At both timepoints the left frontal pole and right substantia nigra/VTA are
significantly improved, compared to baseline measurements, within the salience network
as. The left frontal pole has been thought to be involved in analgesic effects of pain
modulation and regulation of emotional influence on other pain processing (Kalisch et
al., 2005; Salomons et al., 2007; Wiech et al., 2006). As compared to changes seen at 30
minutes, 6-weeks post treatment reflected an increased connectivity of left frontal pole
with ipsilateral mesocortical regions (orbitofrontal insular and ventral striatum/pallidum)
as well as contralateral frontal regions (DLPFC and SMA/preSMA). Similarly, the
mesocortical region of right SN/VTA showed increased connectivity to contralateral
DLPFC 6 weeks post treatment. As most of the treatment patients had medication
overuse prior to the treatment, improvements in regions associated with the mesocortical
dopamine pathway this may be evidence of normalization of impairments caused by
medication overuse (discussed in “mesocorticolimbic pathway” section).
Changes in the ECN at 30-minutes post treatment displayed more improved
connections on a nodal level, than changes at 6-weeks. When comparing changes at 30minutes post treatment, bilateral VLPFC, bilateral DLPFC, bilateral DLPFC/FEF, left
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anterior thalamus, and right lateral parietal significantly improved within the network.
However, when comparing baseline to 6 weeks post treatment, only bilateral DLPFC,
left VLPFC, and left DLPFC improved. The overwhelming involvement of the PFC
regions within the ECN in both 30 minute and 6 weeks would suggest that the regions of
the PFC that improved were not due to long term improvements but rather due to the
cognitive component of pain modulation.
Intranetwork connectivity changes at 30 minutes (for ECN) appear to improve
between regions of the PFC, and between the anterior thalamus and PFC. While these
results are similar to changes at 6 weeks, there are more improvements between regions
of the DLPFC and both dorsal and ventromedial caudate. This increase in functional
connectivity between DLPFC regions with caudate seems to be a more prominent long
term benefit of the SPG treatment. This may imply that medication overuse induced
impairments to regions associated with the cortico-basal ganglia-thalamic pathway
discussed earlier may be normalizing.
In order to assess the relationship of improvements of number of headache days
and QOL measures (PHQ-9, HIT-6), a correlation analysis was conducted on the changes
in network strength (see results section for more details). These correlations indicate a
positive relationship between intranetwork functional connectivity strength and improved
clinical measures. Specifically, less moderate to severe HA days/month and improved
PHQ-9 scores were related to increased fc in the SN, and improved HIT-6 scores were
related to increased fc in the ECN. Interestingly, there was one intranetwork connection
in the SN, however, that had a negative relationship with reduced HA days/month after
treatment. Though this intranetwork connection was not significantly different when
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comparing baseline to 6 week functional connectivity, this negative relationship indicates
that a reduction to the number of moderate to severe headaches days/month after
treatment is related to a weaker intranetwork functional connectivity between the left
subcallosal areas and left SMA/preSMA.
Unfortunately, as the SN and ECN changes mostly reflect PFC and basal ganglia
regions, it is hard to determine if these improvements are related to pain modulation or a
placebo response (Kong et al., 2007; Scott et al., 2008).
5.7 STUDY LIMITATIONS:
As with most scientific studies, the methods of this study are not free from
possible confounds. One possible confound is the variability in analgesic drug use,
which may have had an impact on resting state connectivity. Another potential confound
is that several psychiatric comorbidities of migraine (i.e. anxiety, depression) are
associated with several areas in all the networks examined. However, it is unclear if
these comorbidities are a consequence of modulated brain networks or if they contribute
to the dysfunction. Even though both groups (MOH and nonMOH) had varying degrees
of anxiety/depression (measured with PHQ-9), the MOH group did have a significantly
higher score. However, the average scores for both groups were classified as mild
(nonMOH) and moderate (MOH).
Similarly, allodynia seems to play a large role in connectivity, and both these
groups had varying degrees of allodynia. In a study by Schwedt et al (2014), the
presence of allodynia was indicative of stronger functional connectivity between PAG
and other regions in that are in both our SN and ECN (Schwedt et al., 2014b). This may
have contributed to why we did not observe any functional connectivity differences for
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the PAG, as reported by other migraine studies (Mainero, Boshyan, & Hadjikhani, 2011;
Schwedt et al., 2013; Schwedt et al., 2014b). Additionally, disease duration has also
been shown to have an impact on resting state networks (Chanraud et al., 2014).
However, only one intranetwork connection (left subcallosal area to frontal pole) was
negatively correlated with years with chronic migraine in the nonMOH vs control group.
Lastly, literature on functional connectivity differences in migraine populations
is heavily influenced by episodic migraine and migraine with/without aura. Very few
studies have been completed regarding chronic migraine. Therefore, generalizations
between chronic migraine and other migraine populations is difficult. Additionally, as
we do not have a cohort group of episodic migraineurs, we cannot make assumptions for
that group.
As for the treatment portion of this study, there are a few limitations. One is that
since the treatment was given right before both the “30-minute post treatment scan” and
before the “6 weeks post treatment scan”, it is hard to determine if there is a placebo
response. Another limitation to this study is the small sample size. A larger cohort would
possibly allow more subtle changes to be discovered. Additionally, any neural plasticity
that may have occurred due to the SPG treatment may be too small to detect only after 6
weeks of treatment. A study with a longer follow up period might help improve this
detection.
5.8 FUTURE DIRECTIONS:
Based on the results of this study, further investigation into the mechanisms of
thalamic inhibition systems would help provide a better understanding of its role in the
chronification of pain. For CM without MOH, the impairment seen in the subcallosal
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area will require additional investigation into how this region works with areas outside
the SN. For CM with MOH, a more detailed investigation into the mesocorticolimbic
dopamine and cortico-basal ganglia-thalamic systems may help shed light on a similar
dysfunction to thalamic inhibition systems. Due to the method of this study, there are
many limited factors that cannot determine directionality and relationship between
networks. Future studies would benefit by utilizing granger causality to predict
directionality (Bressler & Menon, 2010).
Investigation into these smaller systems may also help with understanding how
SPG blockade works. With regards to the treatment study, a more comprehensive study
with more patients and additional post treatment scans is warranted. For both parts of
this study, we did collect DTI data, however we lacked resources to analyze this
methodology. Investigation into white matter modulations would also add to this limited
knowledge of the topic we are investigating.
5.9 CONCLUSIONS:
Based on the results of our study, we propose that chronic migraine is a result of
modulated functional brain networks induced by repetitive migraine attacks. By
examining the intranetwork connections, we discovered that disruptions to these
networks could be a consequence of the dysfunction of several smaller systems that
make up the SN and ECN. Both CM groups show similarly disrupted regions of limbic
(SN) and frontal cortex (ECN), however, the two groups present with different
intranetwork connectivity disruptions. Specifically, nonMOH patients appear to have a
widespread disruption between regions of the subcallosal area and other regions of the
SN. Furthermore, in MOH patients we observed additional disruptions to mesocortical
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dopamine (SN) and cortico-basal ganglia-thalamic systems (ECN), which may be a
result of abuse of pain medication. These finding suggest that there is a different pattern
of connectivity impairment unique to each CM group investigated.
In conclusion, we believe that the SN of chronic migraine patients is less
coordinated due to the overwhelmingly increased salience of pain. Additionally, we
propose that the frontal cortex dysfunction of the ECN is a result of conflict of
overlapping resources involved in the cognitive modulation of pain. The DMN, which is
functionally coupled with both the SN and ECN, is consequently manifesting
incoherence. However, this dysfunction may not be permanent, as there is evidence of
ECN and DMN normalization in CM patients after the treatment of repetitive inhibition
of the SPG.
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APPENDIX A: SUPPLEMENTAL METHODS
TABLE A.1: MNI coordinates for each network
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APPENDIX B: SUPPLEMENTAL RESULTS
TABLE B.1: Significant differences in average nodal connectivity strength for each CM
group compared to their matched controls.
CM Group
vs Matched
Controls
DMN

CM Group
(Avg ± SD)

Matched
Controls
(Avg ± SD)

pvalue

CM w/MOH
CM w/o MOH
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0.025
0.002*
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Left SN/VTA
CM w/o MOH
CM w/MOH
Right SN/VTA
CM w/o MOH
CM w/MOH
Left Hypothalamus
CM w/o MOH
CM w/MOH
Right Hypothalamus
CM w/o MOH
CM w/MOH
Right Orbital Frontal insula
CM w/o MOH

0.05 ± 0.17
0.1 ± 0.1
0.02 ± 0.16
0.06 ± 0.11
-0.01 ± 0.13
0.01 ± 0.12
-0.16 ± 0.14
-0.19 ± 0.13
0.1 ± 0.15
0.12 ± 0.14
0.08 ± 0.16
0.11 ± 0.12
0.14 ± 0.17
0.18 ± 0.17

0.19 ± 0.11
0.19 ± 0.11
0.17 ± 0.11
0.16 ± 0.12
0.11 ± 0.1
0.12 ± 0.1
-0.06 ± 0.13
-0.06 ± 0.13
0.2 ± 0.12
0.22 ± 0.12
0.17 ± 0.1
0.19 ± 0.09
0.29 ± 0.12
0.29 ± 0.13

0.011
0.010
0.005*
0.006*
0.007*
0.003*
0.033
0.008*
0.047
0.012
0.048
0.005*
0.008*
0.020

Both CM Groups vs Controls
Left Lateral Parietal
CM w/MOH vs Controls only
Medial Prefrontal
Right Lateral Parietal
CM w/o MOH vs Controls only
Precuneus/PCC

TPN
Both CM Groups vs Controls
Left Frontal Eye Fields

Both CM Groups vs Controls
Left Ventral Striatum-Pallidum
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CM Group
vs Matched
Controls

CM Group
(Avg ± SD)

Matched
Controls
(Avg ± SD)

p-value

CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH

-0.12 ± 0.14
-0.01 ± 0.14
0.07 ± 0.12
0 ± 0.16
-0.06 ± 0.14
-0.04 ± 0.16
0.09 ± 0.15

0 ± 0.17
0.12 ± 0.11
0.15 ± 0.11
0.12 ± 0.12
0.06 ± 0.17
0.11 ± 0.13
0.2 ± 0.1

0.035
0.009*
0.048
0.020
0.033
0.006*
0.018

CM w/o MOH
CM w/o MOH
CM w/o MOH
CM w/o MOH
CM w/o MOH
CM w/o MOH
CM w/o MOH

-0.04 ± 0.21
0.06 ± 0.22
0.19 ± 0.09
0.19 ± 0.09
0.2 ± 0.15
0.02 ± 0.2
0.06 ± 0.14

0.1 ± 0.17
0.2 ± 0.15
0.25 ± 0.13
0.26 ± 0.12
0.27 ± 0.13
0.12 ± 0.17
0.16 ± 0.17

0.026
0.015
0.030
0.013
0.035
0.034
0.041

CM w/MOH
CM w/o MOH
CM w/MOH
CM w/o MOH
CM w/MOH
CM w/o MOH
CM w/MOH
CM w/o MOH
CM w/MOH
CM w/o MOH

0.11 ± 0.08
0.12 ± 0.1
-0.05 ± 0.15
0.01 ± 0.16
0.09 ± 0.1
0.08 ± 0.1
0.08 ± 0.12
0.11 ± 0.11
0.07 ± 0.13
0.01 ± 0.15

0.22 ± 0.08
0.23 ± 0.08
0.11 ± 0.11
0.11 ± 0.12
0.19 ± 0.08
0.2 ± 0.08
0.2 ± 0.08
0.2 ± 0.08
0.17 ± 0.12
0.14 ± 0.11

<0.001*
0.003*
<0.001*
0.030
0.001*
0.002*
0.001*
0.014
0.032
0.022

CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH

0.03 ± 0.12
0.12 ± 0.17
-0.01 ± 0.12
0.06 ± 0.11
0.09 ± 0.11
-0.02 ± 0.15
0.01 ± 0.13

0.17 ± 0.09
0.23 ± 0.11
0.09 ± 0.12
0.17 ± 0.12
0.17 ± 0.12
0.07 ± 0.12
0.09 ± 0.1

0.001*
0.032
0.017
0.007*
0.045
0.044
0.031

SN
CM w/MOH vs Controls only
Left Frontal Pole
Right Supramarginal Gyrus
Left Supramarginal Gyrus
Left DLPFC
Right DLPFC
Right VLPFC
Left SMA/preSMA
CM w/o MOH vs Controls only
Left Subcallosal Area
Right Subcallosal Area
Left Dorsal ACC
Right Dorsal ACC
Left Orbital Frontal insula**
Right Superior Temporal**
Left Temporal Pole

ECN
Both CM Groups vs Controls
Left Lateral Parietal
Right Inferior Frontal Gyrus
Right VLPFC
Left VLPFC
Right DLPFC/FEF
CM w/MOH vs Controls only
Left DLPFC**
Dorsal Medial PFC
Left Orbital Frontal insula
Left Anterior Thalamus**
Right Anterior Thalamus
Right Dorsal Caudate
Right Ventromedial Caudate
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CM Group
vs Matched
Controls

CM Group
(Avg ± SD)

Matched
Controls
(Avg ± SD)

p-value

CM w/o MOH vs Controls only
Left DLPFC/FEF
CM w/o MOH
0.11 ± 0.09
0.18 ± 0.09
0.008*
Right DLPFC**
CM w/o MOH
0.07 ± 0.09
0.15 ± 0.11
0.029
*p<0.01
**borderline significant in the other CM comparison group (see Chapter 3.3)
NOTE: Statistical differences determined using a one-tailed t-test with a threshold of p<0.05

TABLE B.2: Significant differences of intranetwork connections for each CM group vs
their set of age matched controls.
Intranetwork connection
DMN
CM w/o MOH vs Controls only
Left Lateral Parietal x Precuneus/PCC
TPN
CM w/o MOH vs Controls only
Left FEF x Right Intraparietal Sulcus
SN
Both CM Groups vs Controls
Right DLPFC x Right Supramarginal Gyrus
Right DLPFC x Right VLPFC
Right VLPFC x Right SMA/preSMA
CM w/MOH vs Controls only
Left Frontal Pole x Left Superior
Temporal*
Left Frontal Pole x Right Superior
Temporal
Left Frontal Pole x Left Ventral
Striatum/Pallidum*
Left SMA/preSMA x Right Orbital Frontal
insula
Left SMA/preSMA x Right Ventral
Striatum/Pallidum
Left SMA/preSMA x Left Ventral
Striatum/Pallidum
Left SMA/preSMA x Right VLPFC

CM Group
vs Controls

CM Group Controls
p(Avg ± SD) (Avg ± SD) value

CM w/o MOH 0.49 ± 0.30 0.75 ± 0.18 0.003

CM w/o MOH 0.17 ± 0.21 0.35 ± 0.14 0.006

CM w/MOH
CM w/o MOH
CM w/MOH
CM w/o MOH
CM w/MOH
CM w/o MOH

0.29 ± 0.20
0.22 ± 0.20
0.48 ± 0.23
0.47 ± 0.15
0.28 ± 0.20
0.29 ± 0.18

0.47 ± 0.15
0.47 ± 0.16
0.73 ± 0.19
0.71 ± 0.20
0.46 ± 0.15
0.46 ± 0.16

0.003
0.001
0.003
0.001
0.006
0.002

CM w/MOH

0.0 ± 0.17

0.20 ± 0.22 0.007

CM w/MOH

-0.01 ±
0.18

0.18 ± 0.19 0.007

CM w/MOH

0.06 ± 0.18 0.23 ± 0.16 0.008

CM w/MOH

0.47 ± 0.24 0.67 ± 0.14 0.008

CM w/MOH

0.23 ± 0.18 0.41 ± 0.17 0.007

CM w/MOH

0.26 ± 0.15 0.45 ± 0.17 0.002

CM w/MOH

0.14 ± 0.21 0.39 ± 0.22 0.004
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Intranetwork connection
Right DLPFC x Right SMA/preSMA
Left DLPFC x Left Ventral
Striatum/Pallidum
Left DLPFC x Right Ventral
Striatum/Pallidum
Left DLPFC x Right Orbital Frontal insula*
Left DLPFC x Dorsomedial Thalamus
Left DLPFC x Left Dorsal ACC
Right VLPFC x Right Orbital Frontal insula
Right VLPFC x Left Supramarginal Gyrus
Right VLPFC x Right Supramarginal Gyrus
Left Supramarginal Gyrus x Right Ventral
Striatum/Pallidum
Right Supramarginal Gyrus x Left
Hypothalamus
Right Ventral Striatum/Pallidum x
Dorsomedial Thalamus
Right Ventral Striatum/Pallidum x Right
Sup Temporal
Left SN/VTA x Left Orbital Frontal insula
Right SN/VTA x Left Hypothalamus
Right SN/VTA x Right Hypothalamus
Right SN/VTA x Left Supramarginal Gyrus

CM Group
vs Controls
CM w/MOH

CM Group Controls
p(Avg ± SD) (Avg ± SD) value
0.29 ± 0.17 0.48 ± 0.19 0.006

CM w/MOH

0.16 ± 0.15 0.34 ± 0.15 0.002

CM w/MOH

0.12 ± 0.15 0.33 ± 0.16 <0.001

CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH
CM w/MOH

0.20 ± 0.19
0.14 ± 0.19
0.57 ± 0.26
0.21 ± 0.17
0.30 ± 0.26
0.33 ± 0.21

CM w/MOH

0.17 ± 0.15 0.30 ± 0.13 0.009

CM w/MOH

0.21 ± 0.14 0.33 ± 0.09 0.004

CM w/MOH

0.24 ± 0.18 0.41 ± 0.18 0.009

CM w/MOH

0.06 ± 0.19 0.26 ± 0.19 0.005

CM w/MOH
CM w/MOH
CM w/MOH

0.18 ± 0.19
0.11 ± 0.21
0.07 ± 0.23
-0.01 ±
0.14

CM w/MOH

0.39 ± 0.21
0.30 ± 0.13
0.79 ± 0.14
0.42 ± 0.23
0.58 ± 0.29
0.62 ± 0.19

0.008
0.008
0.004
0.007
0.006
<0.001

0.36 ± 0.16 0.006
0.35 ± 0.22 0.003
0.32 ± 0.21 0.003
0.15 ± 0.15 0.002

CM w/o MOH vs Controls only
-0.03 ±
0.17
Left Subcallosal Area x Left Temporal Pole CM w/o MOH 0.26 ± 0.21
Left Subcallosal Area x Left SN/VTA
CM w/o MOH 0.17 ± 0.17
Left Subcallosal Area x Right SN/VTA
CM w/o MOH 0.10 ± 0.21
Left Subcallosal Area x Right Subcallosal
CM w/o MOH 0.55 ± 0.24
Area
Right Subcallosal Area x Right Temporal
CM w/o MOH 0.29 ± 0.24
Pole
Right Subcallosal Area x Right Ventral
CM w/o MOH 0.41 ± 0.18
Striatum/Pallidum
Left Superior Temporal x Left Temporal
CM w/o MOH 0.48 ± 0.26
Pole
Right Superior Temporal x Left Temporal
CM w/o MOH 0.39 ± 0.29
Pole
Right Orbital Frontal insula x Right
CM w/o MOH 0.64 ± 0.24
Temporal Pole
Left Subcallosal Area x Left Frontal Pole*

CM w/o MOH
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0.15 ± 0.15 0.003
0.45 ± 0.20 0.003
0.39 ± 0.21 0.006
0.36 ± 0.15 <0.001
0.80 ± 0.23 0.007
0.48 ± 0.23 0.009
0.57 ± 0.14 0.009
0.71 ± 0.22 0.0099
0.57 ± 0.27 0.009
0.89 ± 0.25 0.002

Intranetwork connection
Left Orbital Frontal insula x Left Ventral
Striatum/Pallidum
Left Orbital Frontal insula x Right Ventral
Striatum/Pallidum
Right VLPFC x Right Hypothalamus
Right Dorsal ACC x Right Orbital Frontal
insula
ECN
Both CM Groups vs Controls
Left DLPFC/FEF x Dorsal Medial PFC
Left Anterior Thalamus x Right VLPFC
CM w/MOH vs Controls only
Left Anterior Thalamus x Right DLPFC
Left Anterior Thalamus x Left DLPFC
Right Anterior Thalamus x Left DLPFC
Right Inferior Frontal Gyrus x Left Anterior
Thalamus
Right Inferior Frontal Gyrus x Right
Anterior Thalamus
Right Inferior Frontal Gyrus x Left DLPFC
Right Inferior Frontal Gyrus x Right
DLPFC
Right Inferior Frontal Gyrus x Left VLPFC
Right Inferior Frontal Gyrus x Right
VLPFC
Right Inferior Frontal Gyrus x Right
Ventromedial Caudate
Right Inferior Frontal Gyrus x Right Dorsal
Caudate
Left VLPFC x Right VLPFC
Left Lateral Parietal x Left DLPFC
Left Lateral Parietal x Left VLPFC

CM Group
vs Controls

CM Group Controls
p(Avg ± SD) (Avg ± SD) value

CM w/o MOH 0.37 ± 0.13 0.51 ± 0.13 0.005
CM w/o MOH 0.33 ± 0.12 0.46 ± 0.12 0.005
CM w/o MOH 0.20 ± 0.15 0.30 ± 0.13 0.007
CM w/o MOH 0.51 ± 0.17 0.67 ± 0.21 0.002

CM w/MOH
CM w/o MOH
CM w/MOH
CM w/o MOH

0.53 ± 0.31
0.56 ± 0.23
0.13 ± 0.14
0.10 ± 0.12

0.79 ± 0.19
0.82 ± 0.19
0.25 ± 0.14
0.25 ± 0.14

0.006
<0.001
0.008
0.008

CM w/MOH
CM w/MOH
CM w/MOH

0.07 ± 0.17 0.29 ± 0.16 <0.001
0.16 ± 0.13 0.32 ± 0.14 0.001
0.14 ± 0.12 0.27 ± 0.16 0.007

CM w/MOH

0.11 ± 0.21 0.38 ± 0.22 0.002

CM w/MOH

0.16 ± 0.23 0.38 ± 0.21 0.005

CM w/MOH

0.08 ± 0.15 0.37 ± 0.19 <0.001

CM w/MOH

0.39 ± 0.24 0.64 ± 0.16 <0.001

CM w/MOH

0.05 ± 0.19 0.24 ± 0.17 0.005

CM w/MOH

0.16 ± 0.18 0.30 ± 0.14 0.003

CM w/MOH

0.03 ± 0.23 0.24 ± 0.10 0.001

CM w/MOH

0.04 ± 0.20 0.21 ± 0.17 0.006

CM w/MOH
CM w/MOH
CM w/MOH

0.57 ± 0.28 0.83 ± 0.23 0.005
0.34 ± 0.24 0.61 ± 0.28 0.004
0.45 ± 0.25 0.71 ± 0.25 0.007

CM w/o MOH vs Controls only
Left Lateral Parietal x Right VLPFC

CM w/o MOH 0.35 ± 0.19 0.57 ± 0.22 0.002

Left DLPFC/FEF x Right Inferior Temporal CM w/o MOH 0.19 ± 0.11 0.30 ± 0.10 0.004
Left DLPFC/FEF x Right DLPFC/FEF
CM w/o MOH 0.22 ± 0.17 0.43 ± 0.24 0.0095
*connection is correlated with a clinical feature (Hit-6, triptan use, PHQ-9, years with CM)
NOTE: Statistical differences determined using a one-tailed t-test with a threshold of p<0.01
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TABLE B.3: Significantly different nodal connectivity strengths in a network when
comparing baseline to 30-minute and 6 weeks post first treatment.
Baseline vs 30 minutes

Left Frontal Pole

Baseline
(Avg ± SD)
-0.15 ± 0.11

30min
(Avg ± SD)
-0.12 ± 0.09

Right SN/VTA

-0.16 ± 0.11

-0.12 ± 0.08

0.009

Left VLPFC

0.06 ± 0.13

0.11 ± 0.07

0.005

Right VLPFC

0.07 ± 0.09

0.11 ± 0.04

0.048

Left DLPFC/FEF

-0.02 ± 0.11

0.04 ± 0.09

0.041

Right DLPFC/FEF

0.06 ± 0.07

0.13 ± 0.07

0.013

Left DLPFC

0.02 ± 0.13

0.08 ± 0.11

0.0096

Right DLPFC

0.04 ± 0.13

0.09 ± 0.11

0.026

Left Anterior Thalamus

0.02 ± 0.10

0.13 ± 0.06

0.022

Right Lateral Parietal

0.04 ± 0.07

0.10 ± 0.10

0.049

Right Lateral Parietal

Baseline
(Avg ± SD)
0.60 ± 0.17

6 weeks
(Avg ± SD)
0.64 ± 0.16

Precuneus/PCC

0.60 ± 0.20

0.65 ± 0.18

0.036

Left Frontal Pole

-0.16 ± 0.11

-0.09 ± 0.15

0.027

Right SN/VTA

-0.18 ± 0.11

-0.16 ± 0.10

0.034

Left VLPFC

0.05 ± 0.13

0.12 ± 0.13

0.004

Left DLPFC

0.00 ± 0.12

0.08 ± 0.13

0.004

Left DLPFC/FEF

-0.02 ± 0.11

0.04 ± 0.10

0.009

Right DLPFC/FEF

0.04 ± 0.07

0.08 ± 0.10

0.004

Network
SN

ECN

Node

p-value
0.009

Baseline vs 6 Weeks
Network
DMN
SN

ECN

Node

p-value
0.019

NOTE: Statistical differences determined using a one-tailed t-test with a threshold of p<0.05
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TABLE B.4: Significantly different intranetwork connections strengths when comparing
baseline to 30-minute and 6-weeks post treatment.
Baseline vs 30 minutes

Before TX
(Avg ± SD)
0.07 ± 0.15
0.04 ± 0.17
0.16 ± 0.18
0.21 ± 0.19
0.33 ± 0.2

After TX
(Avg ± SD)
0.14 ± 0.12
0.1 ± 0.12
0.23 ± 0.08
0.3 ± 0.13
0.36 ± 0.16

SN
p-value
Left Frontal Pole x Right Hypothalamus
0.046
Left Frontal Pole x Right Ventral Striatum Pallidum
0.041
Left Frontal Pole x Right Orbital Frontal insula
0.019
Right DLPFC x Right Orbital Frontal insula
0.009
Left PAG x Right Orbital Frontal insula
0.019
ECN
Left DLPFC x Right DLPFC/FEF
0.21 ± 0.22 0.33 ± 0.25
0.019
Left DLPFC x Right Anterior Thalamus
0.16 ± 0.12 0.24 ± 0.08
0.021
Left DLPFC x Left Anterior Thalamus
0.17 ± 0.12
0.3 ± 0.1
0.010
Right DLPFC x Left Anterior Thalamus
0.07 ± 0.19 0.15 ± 0.09
0.028
Right DLPFC/FEF x Left VLPFC
0.25 ± 0.15 0.34 ± 0.12
0.010
Baseline vs 6 Weeks
Before TX
After TX
DMN
(Avg ± SD) (Avg ± SD) p-value
Precuneus/PCC x Right Lateral Parietal
0.72 ± 0.32 0.79 ± 0.29
0.005
Precuneus/PCC x Medial PFC
0.47 ± 0.19 0.55 ± 0.20
0.024
SN
Left Frontal Pole x Left Orbital Frontal insula
0.03 ± 0.18 0.11 ± 0.21
0.046
Left Frontal Pole x Right Orbital Frontal insula
0.15 ± 0.18 0.26 ± 0.28
0.012
Left Frontal Pole x Left Ventral Striatum Pallidum
0.02 ± 0.19 0.14 ± 0.19
0.022
Left Frontal Pole x Right Ventral Striatum Pallidum 0.05 ± 0.17 0.22 ± 0.19
0.021
Left Frontal Pole x Right SMA/preSMA
0.25 ± 0.25 0.32 ± 0.3
0.038
Left Frontal Pole x Right DLPFC
0.43 ± 0.15 0.62 ± 0.2
0.032
Right SN/VTA x Left DLPFC
-0.1 ± 0.12 0.03 ± 0.17
0.040
Right SN/VTA x Right Temporal Pole
0.00 ± 0.23 0.08 ± 0.2
0.020
Left Superior Temporal x Right Supramarginal Gyrus** 0.19 ± 0.33 0.13 ± 0.25
0.030
ECN
Left DLPFC x Left VLPFC
0.6 ± 0.14 0.61 ± 0.23
0.019
Left DLPFC x Right Anterior Thalamus
0.17 ± 0.11 0.27 ± 0.16
0.027
Left DLPFC x Right Ventromedial Caudate
0.15 ± 0.12 0.2 ± 0.17
0.049
Left DLPFC x Right DLPFC/FEF
0.2 ± 0.21 0.34 ± 0.23
0.021
Right DLPFC/FEF x Left VLPFC
0.24 ± 0.15 0.29 ± 0.18
0.043
Right DLPFC/FEF x Right Dorsal Caudate
0.01 ± 0.14 0.12 ± 0.18
0.028
Left DLPFC/FEF x Right Ventromedial Caudate
0 ± 0.14
0.04 ± 0.14
0.011
Left DLPFC/FEF x Right Anterior Thalamus
0.03 ± 0.17 0.18 ± 0.17
0.028
**Controls were non-significantly lower on average when comparing CM to controls
NOTE: Statistical differences determined using a two-tailed t-test with a threshold of p<0.05
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